106 results on '"K. Dorman"'
Search Results
2. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
- Author
-
L. Weiss, K. Heinrich, D. Zhang, K. Dorman, K. Rühlmann, K. Hasselmann, F. Klauschen, J. Kumbrink, A. Jung, M. Rudelius, A. Mock, Steffen Ormanns, W. G. Kunz, D. Roessler, G. Beyer, S. Corradini, L. Heinzerling, M. Haas, M. von Bergwelt-Baildon, S. Boeck, V. Heinemann, and C. B. Westphalen
- Subjects
Cancer Research ,Oncology ,General Medicine - Abstract
Purpose For patients with cancer of unknown primary (CUP), treatment options are limited. Precision oncology, the interplay of comprehensive genomic profiling (CGP) and targeted therapies, aims to offer additional treatment options to patients with advanced and hard-to-treat cancers. We aimed to highlight the use of a molecular tumor board (MTB) in the therapeutic management of CUP patients. Methods In this single-center observational study, CUP patients, presented to the MTB of the Comprehensive Cancer Center Munich LMU, a tertiary care center, were analyzed retrospectively. Descriptive statistics were applied to describe relevant findings. Results Between June 2016 and February 2022, 61 patients with unfavorable CUP were presented to the MTB, detected clinically relevant variants in 74% (45/61) of patients, of which 64% (29/45) led to therapeutic recommendation. In four out of 29 patients (14%), the treatment recommendations were implemented, unfortunately without resulting in clinical benefit. Reasons for not following the therapeutic recommendation were mainly caused by the physicians’ choice of another therapy (9/25, 36%), especially in the context of worsening of general condition, lost to follow-up (7/25, 28%) and death (6/25, 24%). Conclusion CGP and subsequent presentation to a molecular tumor board led to a high rate of therapeutic recommendations in patients with CUP. Recommendations were only implemented at a low rate; however, late GCP diagnostic and, respectively, MTB referral were found more frequent for the patients with implemented treatment. This contrast underscores the need for early implementation of CGP into the management of CUP patients.
- Published
- 2023
- Full Text
- View/download PDF
3. A Novel Mobile Device-Based Navigation System for Placement of Posterior Spinal Fixation
- Author
-
Joseph, Driver, John K, Dorman, and John H, Chi
- Subjects
Lumbar Vertebrae ,Pedicle Screws ,Computers, Handheld ,Cadaver ,Humans ,Reproducibility of Results ,Surgery ,Neurology (clinical) - Abstract
Spinal navigation technology has revolutionized the field of spine surgery. However, adoption has not been universal. Reasons include cost, interruption in surgical workflow, increased OR time, and potential implant incompatibility, among others. A technology that maintains performance but alleviates these drawbacks would be valuable. A mobile device-based navigation system has been developed which relies on the iOS platform and the gyroscopic-on-chip technology, therein to guide accurate placement of pedicle screws. This system maintains a minimal footprint and resolves difficulty with line-of-sight interruption and attention shift.To evaluate the accuracy and reliability of this device in a preclinical setting.A cadaver study was performed involving 13 surgeons placing 26 pedicle screws using the novel assistive technology. CT scans were then performed, and accuracy was assessed by designating each screw a Gertzbein-Robbins score. In addition, bench top table testing was performed. This consisted of 360 tests of both the accuracy of the device's pitch and roll, corresponding to the rotation about the device's x-axis and y-axis, respectively.The mean Gertzbein-Robbins score of the 26 screws placed in the cadaver study was 1.29. The mean deviation from centerline pedicle placement was 0.66 mm, with a standard deviation of 1.52 mm. The bench top study results included a mean pitch error of 0.17° + 0.09° and a mean roll error of 0.29 + 0.21.The novel mobile device-based navigation system for placement of pedicle screws presented here demonstrates high levels of accuracy and reliability in the preclinical setting.
- Published
- 2022
- Full Text
- View/download PDF
4. Differences in obstetrical care and outcomes associated with the proportion of the obstetrician's shift completed
- Author
-
Lynn M. Yee, Paula McGee, Jennifer L. Bailit, Ronald J. Wapner, Michael W. Varner, John M. Thorp, Steve N. Caritis, Mona Prasad, Alan T.N. Tita, George R. Saade, Yoram Sorokin, Dwight J. Rouse, Sean C. Blackwell, Jorge E. Tolosa, G. Mallett, W. Grobman, M. Ramos-Brinson, A. Roy, L. Stein, P. Campbell, C. Collins, N. Jackson, M. Dinsmoor, J. Senka, K. Paychek, A. Peaceman, M. Talucci, M. Zylfijaj, Z. Reid, R. Leed, J. Benson, S. Forester, C. Kitto, S. Davis, M. Falk, C. Perez, K. Hill, A. Sowles, J. Postma, S. Alexander, G. Andersen, V. Scott, V. Morby, K. Jolley, J. Miller, B. Berg, K. Dorman, J. Mitchell, E. Kaluta, K. Clark, K. Spicer, S. Timlin, K. Wilson, L. Moseley, K. Leveno, M. Santillan, J. Price, K. Buentipo, V. Bludau, T. Thomas, L. Fay, C. Melton, J. Kingsbery, R. Benezue, H. Simhan, M. Bickus, D. Fischer, T. Kamon, D. DeAngelis, B. Mercer, C. Milluzzi, W. Dalton, T. Dotson, P. McDonald, C. Brezine, A. McGrail, C. Latimer, L. Guzzo, F. Johnson, L. Gerwig, S. Fyffe, D. Loux, S. Frantz, D. Cline, S. Wylie, J. Iams, M. Wallace, A. Northen, J. Grant, C. Colquitt, D. Rouse, W. Andrews, J. Moss, A. Salazar, A. Acosta, G. Hankins, N. Hauff, L. Palmer, P. Lockhart, D. Driscoll, L. Wynn, C. Sudz, D. Dengate, C. Girard, S. Field, P. Breault, F. Smith, N. Annunziata, D. Allard, J. Silva, M. Gamage, J. Hunt, J. Tillinghast, N. Corcoran, M. Jimenez, F. Ortiz, P. Givens, B. Rech, C. Moran, M. Hutchinson, Z. Spears, C. Carreno, B. Heaps, G. Zamora, J. Seguin, M. Rincon, J. Snyder, C. Farrar, E. Lairson, C. Bonino, W. Smith, K. Beach, S. Van Dyke, S. Butcher, E. Thom, M. Rice, Y. Zhao, V. Momirova, R. Palugod, B. Reamer, M. Larsen, C. Spong, S. Tolivaisa, and J.P. VanDorsten
- Subjects
Episiotomy ,Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Psychological intervention ,Personnel Staffing and Scheduling ,Perineum ,Lacerations ,Article ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Obstetrics and gynaecology ,Pregnancy ,Intensive Care Units, Neonatal ,Physicians ,Medicine ,Humans ,030212 general & internal medicine ,Quality of Health Care ,030219 obstetrics & reproductive medicine ,business.industry ,Vaginal delivery ,Cesarean Section ,Obstetrics and Gynecology ,Workload ,Delivery mode ,Obstetric Labor Complications ,Obstetrics ,Logistic Models ,Emergency medicine ,Cohort ,Apgar Score ,Apgar score ,Female ,business - Abstract
Understanding and improving obstetrical quality and safety is an important goal of professional societies, and many interventions such as checklists, safety bundles, educational interventions, or other culture changes have been implemented to improve the quality of care provided to obstetrical patients. Although many factors contribute to delivery decisions, a reduced workload has addressed how provider issues such as fatigue or behaviors surrounding impending shift changes may influence the delivery mode and outcomes.The objective was to assess whether intrapartum obstetrical interventions and adverse outcomes differ based on the temporal proximity of the delivery to the attending's shift change.This was a secondary analysis from a multicenter obstetrical cohort in which all patients with cephalic, singleton gestations who attempted vaginal birth were eligible for inclusion. The primary exposure used to quantify the relationship between the proximity of the provider to their shift change and a delivery intervention was the ratio of time from the most recent attending shift change to vaginal delivery or decision for cesarean delivery to the total length of the shift. Ratios were used to represent the proportion of time completed in the shift by normalizing for varying shift lengths. A sensitivity analysis restricted to patients who were delivered by physicians working 12-hour shifts was performed. Outcomes chosen included cesarean delivery, episiotomy, third- or fourth-degree perineal laceration, 5-minute Apgar score of4, and neonatal intensive care unit admission. Chi-squared tests were used to evaluate outcomes based on the proportion of the attending's shift completed. Adjusted and unadjusted logistic models fitting a cubic spline (when indicated) were used to determine whether the frequency of outcomes throughout the shift occurred in a statistically significant, nonlinear pattern RESULTS: Of the 82,851 patients eligible for inclusion, 47,262 (57%) had ratio data available and constituted the analyzable sample. Deliveries were evenly distributed throughout shifts, with 50.6% taking place in the first half of shifts. There were no statistically significant differences in the frequency of cesarean delivery, episiotomy, third- or fourth-degree perineal lacerations, or 5-minute Apgar scores of4 based on the proportion of the shift completed. The findings were unchanged when evaluated with a cubic spline in unadjusted and adjusted logistic models. Sensitivity analyses performed on the 22.2% of patients who were delivered by a physician completing a 12-hour shift showed similar findings. There was a small increase in the frequency of neonatal intensive care unit admissions with a greater proportion of the shift completed (adjusted P=.009), but the findings did not persist in the sensitivity analysis.Clinically significant differences in obstetrical interventions and outcomes do not seem to exist based on the temporal proximity to the attending physician's shift change. Future work should attempt to directly study unit culture and provider fatigue to further investigate opportunities to improve obstetrical quality of care, and additional studies are needed to corroborate these findings in community settings.
- Published
- 2021
5. Reaching Out Through Reading: Service Learning Adventures with Literature
- Author
-
Carrie Sorby Duits, Adelle K. Dorman
- Published
- 1998
6. Failure of an ICD to Deliver Antitachycardia Therapy against Recurrent, Sustained Ventricular Tachycardia: What's the Mechanism?
- Author
-
Evangelos Diamantakos, Luis A. Pires, Andrea K. Dorman, and Michael C. Willoughby
- Subjects
medicine.medical_specialty ,Text mining ,Sustained ventricular tachycardia ,Defibrillation ,business.industry ,Mechanism (biology) ,medicine.medical_treatment ,Internal medicine ,medicine ,Cardiology ,General Medicine ,Cardiology and Cardiovascular Medicine ,business - Published
- 2015
- Full Text
- View/download PDF
7. Defining failed induction of labor
- Author
-
William A. Grobman, Jennifer Bailit, Yinglei Lai, Uma M. Reddy, Ronald J. Wapner, Michael W. Varner, John M. Thorp, Kenneth J. Leveno, Steve N. Caritis, Mona Prasad, Alan T.N. Tita, George Saade, Yoram Sorokin, Dwight J. Rouse, Sean C. Blackwell, Jorge E. Tolosa, G. Mallett, M. Ramos-Brinson, A. Roy, L. Stein, P. Campbell, C. Collins, N. Jackson, M. Dinsmoor, J. Senka, K. Paychek, A. Peaceman, M. Talucci, M. Zylfijaj, Z. Reid, R. Leed, J. Benson, S. Forester, C. Kitto, S. Davis, M. Falk, C. Perez, K. Hill, A. Sowles, J. Postma, S. Alexander, G. Andersen, V. Scott, V. Morby, K. Jolley, J. Miller, B. Berg, K. Dorman, J. Mitchell, E. Kaluta, K. Clark, K. Spicer, S. Timlin, K. Wilson, L. Moseley, M. Santillan, J. Price, K. Buentipo, V. Bludau, T. Thomas, L. Fay, C. Melton, J. Kingsbery, R. Benezue, H. Simhan, M. Bickus, D. Fischer, T. Kamon, D. DeAngelis, B. Mercer, C. Milluzzi, W. Dalton, T. Dotson, P. McDonald, C. Brezine, A. McGrail, C. Latimer, L. Guzzo, F. Johnson, L. Gerwig, S. Fyffe, D. Loux, S. Frantz, D. Cline, S. Wylie, J. Iams, M. Wallace, A. Northen, J. Grant, C. Colquitt, D. Rouse, W. Andrews, J. Moss, A. Salazar, A. Acosta, G. Hankins, N. Hauff, L. Palmer, P. Lockhart, D. Driscoll, L. Wynn, C. Sudz, D. Dengate, C. Girard, S. Field, P. Breault, F. Smith, N. Annunziata, D. Allard, J. Silva, M. Gamage, J. Hunt, J. Tillinghast, N. Corcoran, M. Jimenez, F. Ortiz, P. Givens, B. Rech, C. Moran, M. Hutchinson, Z. Spears, C. Carreno, B. Heaps, G. Zamora, J. Seguin, M. Rincon, J. Snyder, C. Farrar, E. Lairson, C. Bonino, W. Smith, K. Beach, S. Van Dyke, S. Butcher, E. Thom, M. Rice, Y. Zhao, P. McGee, V. Momirova, R. Palugod, B. Reamer, M. Larsen, C. Spong, S. Tolivaisa, and J.P. Van Dorsten
- Subjects
Adult ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Oxytocin ,Chorioamnionitis ,Article ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Oxytocics ,medicine ,Humans ,Rupture of membranes ,Labor, Induced ,030212 general & internal medicine ,030219 obstetrics & reproductive medicine ,Cesarean Section ,Vaginal delivery ,Obstetrics ,business.industry ,Cephalic presentation ,Postpartum Hemorrhage ,Obstetrics and Gynecology ,medicine.disease ,United States ,Labor induction ,Cohort ,Gestation ,Female ,business ,Cervical Ripening ,medicine.drug - Abstract
BACKGROUND: While there are well-accepted standards for the diagnosis of arrested active-phase labor, the definition of a "failed" induction of labor remains less certain. One approach to diagnosing a failed induction is based on the duration of the latent phase. However, a standard for the minimum duration that the latent phase of a labor induction should continue, absent acute maternal or fetal indications for cesarean delivery, remains lacking. OBJECTIVE: The objective of this study was to determine the frequency of adverse maternal and perinatal outcomes as a function of the duration of the latent phase among nulliparous women undergoing labor induction. METHODS: This study is based on data from an obstetric cohort of women delivering at 25 U.S. hospitals from 2008-2011. Nulliparous women who had a term singleton gestation in the cephalic presentation were eligible for this analysis if they underwent a labor induction. Consistent with prior studies, the latent phase was determined to begin once cervical ripening had ended, oxytocin was initiated and rupture of membranes (ROM) had occurred, and was determined to end once 5 cm dilation was achieved. The frequencies of cesarean delivery, as well as of adverse maternal (e.g., cesarean delivery, postpartum hemorrhage, chorioamnionitis) and perinatal outcomes (e.g., a composite frequency of either seizures, sepsis, bone or nerve injury, encephalopathy, or death), were compared as a function of the duration of the latent phase (analyzed with time both as a continuous measure and categorized in 3-hour increments). RESULTS: A total of 10,677 women were available for analysis. In the vast majority (96.4%) of women, the active phase had been reached by 15 hours. The longer the duration of a woman's latent phase, the greater her chance of ultimately undergoing a cesarean delivery (P
- Published
- 2018
- Full Text
- View/download PDF
8. Abstracts from the 4th ImmunoTherapy of Cancer Conference
- Author
-
J. Ženka, V. Caisová, O. Uher, P. Nedbalová, K. Kvardová, K. Masáková, G. Krejčová, L. Paďouková, I. Jochmanová, K. I. Wolf, J. Chmelař, J. Kopecký, L. Loumagne, J. Mestadier, S. D’agostino, A. Rohaut, Y. Ruffin, V. Croize, O. Lemaître, S. S. Sidhu, S. Althammer, K. Steele, M. Rebelatto, T. Tan, T. Wiestler, A. Spitzmueller, R. Korn, G. Schmidt, B. Higgs, X. Li, L. Shi, X. Jin, K. Ranade, S. Koeck, A. Amann, G. Gamerith, M. Zwierzina, E. Lorenz, H. Zwierzina, J. Kern, M. Riva, T. Baert, A. Coosemans, R. Giovannoni, E. Radaelli, W. Gsell, U. Himmelreich, M. Van Ranst, F. Xing, W. Qian, C. Dong, X. Xu, S. Guo, Q. Shi, D. Quandt, B. Seliger, C. Plett, D. C. Amberger, A. Rabe, D. Deen, Z. Stankova, A. Hirn, Y. Vokac, J. Werner, D. Krämer, A. Rank, C. Schmid, H. Schmetzer, M. Guerin, J. M. Weiss, F. Regnier, G. Renault, L. Vimeux, E. Peranzoni, V. Feuillet, M. Thoreau, T. Guilbert, A. Trautmann, N. Bercovici, F. Doraneh-Gard, C. L. Boeck, C. Gunsilius, C. Kugler, J. Schmohl, D. Kraemer, B. Ismann, H. M. Schmetzer, A. Markota, C. Ochs, P. May, A. Gottschlich, J. Suárez Gosálvez, C. Karches, D. Wenk, S. Endres, S. Kobold, T. Hilmenyuk, R. Klar, F. Jaschinski, F. Augustin, C. Manzl, E. Hoflehner, P. Moser, B. Zelger, S. Köck, G. Schäfer, D. Öfner, H. Maier, S. Sopper, H. Prado-Garcia, S. Romero-Garcia, R. Sandoval-Martínez, A. Puerto-Aquino, J. Lopez-Gonzalez, U. Rumbo-Nava, A. Van Hoylandt, P. Busschaert, I. Vergote, J. Laengle, K. Pilatova, E. Budinska, B. Bencsikova, R. Sefr, R. Nenutil, V. Brychtova, L. Fedorova, B. Hanakova, L. Zdrazilova-Dubska, Chris Allen, Yuan-Chieh Ku, Warren Tom, Yongming Sun, Alex Pankov, Tim Looney, Fiona Hyland, Janice Au-Young, Ann Mongan, A. Becker, J. B. L. Tan, A. Chen, K. Lawson, E. Lindsey, J. P. Powers, M. Walters, U. Schindler, S. Young, J. C. Jaen, S. Yin, Y. Chen, I. Gullo, G. Gonçalves, M. L. Pinto, M. Athelogou, G. Almeida, R. Huss, C. Oliveira, F. Carneiro, C. Merz, J. Sykora, K. Hermann, R. Hussong, D. M. Richards, H. Fricke, O. Hill, C. Gieffers, M. P. Pinho, J. A. M. Barbuto, S. E. McArdle, G. Foulds, J. N. Vadakekolathu, T. M. A. Abdel-Fatah, C. Johnson, S. Hood, P. Moseley, R. C. Rees, S. Y. T. Chan, A. G. Pockley, S. Rutella, C. Geppert, A. Hartmann, K. Senthil Kumar, M. Gokilavani, S. Wang, M. Redondo-Müller, K. Heinonen, V. Marschall, M. Thiemann, L. Zhang, B. Mao, Y. Jin, G. Zhai, Z. Li, Z. Wang, X. An, M. Qiao, J. Zhang, J. Weber, H. Kluger, R. Halaban, M. Sznol, H. Roder, J. Roder, J. Grigorieva, S. Asmellash, K. Meyer, A. Steingrimsson, S. Blackmon, R. Sullivan, W. Sutanto, T. Guenther, F. Schuster, H. Salih, F. Babor, A. Borkhardt, Y. Kim, I. Oh, C. Park, S. Ahn, K. Na, S. Song, Y. Choi, A. Poprach, R. Lakomy, I. Selingerova, R. Demlova, S. Kozakova, D. Valik, K. Petrakova, R. Vyzula, D. Aguilar-Cazares, M. Galicia-Velasco, C. Camacho-Mendoza, L. Islas-Vazquez, R. Chavez-Dominguez, C. Gonzalez-Gonzalez, J. S. Lopez-Gonzalez, S. Yang, K. D. Moynihan, M. Noh, A. Bekdemir, F. Stellacci, D. J. Irvine, B. Volz, K. Kapp, D. Oswald, B. Wittig, M. Schmidt, R. Kleef, A. Bohdjalian, D. McKee, R. W. Moss, Mesha Saeed, Sara Zalba, Reno Debets, Timo L. M. ten Hagen, S. Javed, J. Becher, F. Koch-Nolte, F. Haag, E. M. Gordon, K. K. Sankhala, N. Stumpf, W. Tseng, S. P. Chawla, N. González Suárez, G. Bergado Báez, M. Cruz Rodríguez, A. Gutierrez Pérez, L. Chao García, D. Hernández Fernández, J. Raymond Pous, B. Sánchez Ramírez, C. Jacoberger-Foissac, H. Saliba, C. Seguin, A. Brion, B. Frisch, S. Fournel, B. Heurtault, T. Otterhaug, M. Håkerud, A. Nedberg, V. Edwards, P. Selbo, A. Høgset, T. Jaitly, J. Dörrie, N. Schaft, S. Gross, B. Schuler-Thurner, S. Gupta, L. Taher, G. Schuler, J. Vera, F. Rataj, F. Kraus, S. Grassmann, M. Chaloupka, S. Lesch, C. Heise, B. M. Loureiro Cadilha, and K. Dorman
- Subjects
Pharmacology ,Cancer Research ,Oncology ,Immunology ,medicine ,Molecular Medicine ,Immunology and Allergy ,Cancer ,Identification (biology) ,Computational biology ,Biology ,medicine.disease ,Epitope - Published
- 2017
- Full Text
- View/download PDF
9. C-37 Music and Cognitive Aging Across Species
- Author
-
R Kauffman and K Dorman
- Subjects
Cognitive aging ,Psychiatry and Mental health ,Clinical Psychology ,Neuropsychology and Physiological Psychology ,General Medicine ,Psychology ,humanities ,Cognitive psychology - Abstract
Objective Recent research has revealed that dogs suffer from bestial boredom, which is the degeneration of the brain due to lack of stimulation. To prevent this we looked at everyday stimulation owners could leave for their dogs, such as different types of audio. Within music there are various types that effect dog behavior differently. We not only looked at this stimulation within dogs to help prevent bestial boredom, but then connected this to Alzheimer's patients. There are multiple studies out that show the benefits of music before and during the onset of Alzheimer’s. We find this to be true with dementia in dogs too. A review of the research reveals there to be a lack of consensus regarding the efficacy of music in psychological practice. We believe this is because different music serves different functions, and because of familiarity. Data Selection Articles chosen for the meta analysis had to show the connection between music and canines, music and Alzheimer’s patients, and neurodegeneration in humans and within canines. Data Synthesis We conducted a meta analysis to review and analyze whether researchers have taken different forms/styles of music into account in their studies. Conclusions Music is a significant factor for cognitive functioning and aging in both dogs and humans. There are not many studies out there about the effect of music on dogs. The few studies that are out there used kenneled dogs, therefore studies should also be conducted on dogs with homes to see if familiar music has more of an effect.
- Published
- 2019
- Full Text
- View/download PDF
10. Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria
- Author
-
E. K. Dorman, Caroline Shulman, Ken Kawuondo, Trine Staalsoe, Kevin Marsh, and Lars Hviid
- Subjects
Sulfadoxine ,medicine.medical_treatment ,Pregnancy Trimester, Third ,Immunology ,Antibodies, Protozoan ,Antigens, Protozoan ,Microbiology ,Immunoglobulin G ,Drug Administration Schedule ,Antimalarials ,stomatognathic system ,Pregnancy ,Placenta ,parasitic diseases ,medicine ,Animals ,Humans ,Malaria, Falciparum ,reproductive and urinary physiology ,biology ,Plasmodium falciparum ,medicine.disease ,biology.organism_classification ,Sulfadoxine/pyrimethamine ,Drug Combinations ,Infectious Diseases ,medicine.anatomical_structure ,Pyrimethamine ,Pregnancy Complications, Parasitic ,embryonic structures ,biology.protein ,Parasitology ,Female ,Fungal and Parasitic Infections ,Malaria ,medicine.drug - Abstract
Pregnancy-associated malaria (PAM) is an important cause of maternal and neonatal suffering. It is caused by Plasmodium falciparum capable of inhabiting the placenta through expression of particular variant surface antigens (VSA) with affinity for proteoglycans such as chondroitin sulfate A. Protective immunity to PAM develops following exposure to parasites inhabiting the placenta, and primigravidae are therefore particularly susceptible to PAM. The adverse consequences of PAM in primigravidae are preventable by intermittent preventive treatment (IPTp), where women are given antimalarials at specified intervals during pregnancy, but this may interfere with acquisition of protective PAM immunity. We found that Kenyan primigravidae receiving sulfadoxine-pyrimethamine IPTp had significantly lower levels of immunoglobulin G (IgG) with specificity for the type of parasite-encoded VSA—called VSA PAM —that specifically mediate protection against PAM than did women receiving a placebo. VSA PAM -specific IgG levels depended on the number of IPTp doses received and were sufficiently low to be of clinical concern among multidose recipients. Our data suggest that IPTp should be extended to women of all parities, in line with current World Health Organization recommendations.
- Published
- 2016
11. Bethune Round Table 2012: 12th Annual Conference: Filling the GapImpact of international collaboration on surgical services in a Nigerian tertiary centreSurgeons OverSeas Assessment of Surgical Needs (SOSAS) Rwanda: a useful rural health experience for medical studentsPreinternship Nigerian medical graduates lack basic musculoskeletal competencyDecompressive craniectomy: a low-cost surgical technique from a developing countryEfficacy of surgical management with manual vacuum aspiration versus medical management with misoprostol for evacuation of Lrst trimester miscarriages: a randomized trial in PakistanGaps in workforce for surgical care of children in Nigeria: increasing capacity through international partnershipsAnalyses of the gap between surgical resident and faculty surgeons concerning operating theatre teaching: report from Addis Ababa University, EthiopiaIntroduction of structured operative obstetric course at Mbarara Regional Referral Hospital with resultant reduction in maternal mortalityA training cascade for Ethiopian surgical and obstetrical care: an interprofessional, educational, leadership and skills training programUndergraduate surgery clerkship and the choice of surgery as a career: perspective from a developing countryIntramedullary nail versus external Lxation in management of open tibia fractures: experience in a developing countryThe College of Surgeons of East, Central and Southern Africa (COSECSA) Llling the gap; increasing the number of surgeonsClinical officer surgical training in Africa: COST-AfricaSecondary neuronal injuries following cervical spine trauma: audit of 68 consecutive patients admitted to neurosurgical services in Enugu, NigeriaCapacity building and workforce expansion in surgery, anesthesia and perioperative care: the GPAS model in UgandaKnowledge retention surveys: identifying the effectiveness of a road safety education program in Dar es Salaam, TanzaniaA tale of 2 fellowships: a comparative analysis of Canadian and East-African pediatric surgical trainingOutcomes of closed diaphyseal femur fractures treated with the SIGN nailManaging surgical emergencies: delivering a new course for the College of Surgeons of East Central and Southern AfricaAn evaluation of the exam for the University of Guyana Diploma in SurgeryPriority setting for health resource allocation in Brazil: a scoping literature reviewForeign aid effects on orthopedic capacity at the Hospital Saint Nicholas, HaitiReTHINK aid: international maternal health collaborationsEffect of electronic medical record implementation on patient and staff satisfaction, and chart completeness in a resource-limited antenatal clinic in KenyaImplementation of awake craniotomy in the developing world: data from China, Indonesia and AfricaRegionalization of diabetes care In Guyana, South AmericaQuantifying the burden of pediatric surgical disease due to delayed access to careImplementation of oncology surgery in Western Kenya
- Author
-
B. Rosen, D. Poenaru, I. Bhoj, K. Howe, A. Gray, R. Gill, J. Friedman, F. Ferri-de-Barros, R. J. Fairfull Smith, J. S. Dreyer, S. Carsen, R. Baird, K. Zimmerman, C. Mijumbi, W. C. Mezue, M. Labib, P. G. Jani, E. Oluwadare, S. O. Ekenze, M. Derbew, I. Bonet, A. Bekele, E. A. Ameh, S. Ali, A. Olufemi Adeleye, T. E. Nottidge, F. Niyonkuru, A. A. Nasir, A. S. Yusuf, L. O. Abdur-Rahman, B. A. Ahmed, D. Panikar, M. K. Abraham, R. T. Petroze, R. S. Groen, E. Ntaganda, A. L. Kushner, J. Forrest Calland, P. Kyamanywa, U. Ekrikpo, A. O. Ifesanya, R. E. Nnabuko, S. Batool Mazhar, B. Kotisso, S. Shiferaw, J. Ngonzi, K. Dorman, N. Byrne, L. Satterthwaite, R. Pittini, T. Tajirian, R. Kneebone, F. Bello, D. Desalegn, F. Henok, A. Dubrowsk, F. O. Ugwumba, U. M. Obi, I. C. Ikem, L. M. Oginni, A. Howard, E. Onyiah, I. C. Iloabachie, S. C. Ohaegbulam, S. Kaggwa, J. Tindimwebwa, J. Mabweijano, M. Lipnick, G. Dubowitz, L. Goetz, S. Jayaraman, A. Kwizera, D. Ozgediz, J. Matagane, T. Bishop, A. Guerrero, M. Ganey, S. Park, D. Simon, L. G. Zirkle, R. J. Feibel, J. A. F. Hannay, R. H. S. Lane, B. H. Cameron, M. Rambaran, J. Gibson, A. Costas, J. G. Meara, M. St-Albin, G. Dyer, P. Rama Devi, C. Henshaw, J. Wright, J. Leah, R. F. Spitzer, D. Caloia, E. Omenge, B. Chemwolo, G. Zhou, J. July, T. Totimeh, R. Mahmud, M. Bernstein, B. Ostrow, J. Lowe, C. Lawton, L. Lee Kozody, P. Coutts, H. Nesbeth, A. Revoredo, R. Kirton, G. Sibbald, J. Dodge, C. Giede, W. Jimenez, P. Cibulska, S. Sinesat, M. Bernardini, J. McAlpine, S. Finlayson, D. Miller, O. Elkanah, P. Itsura, and L. Elit
- Subjects
Surgery - Published
- 2012
- Full Text
- View/download PDF
12. Neonatal outcomes of elective early-term births after demonstrated fetal lung maturity
- Author
-
Alan T.N. Tita, Kathleen A. Jablonski, Jennifer L. Bailit, William A. Grobman, Ronald J. Wapner, Uma M. Reddy, Michael W. Varner, John M. Thorp, Kenneth J. Leveno, Steve N. Caritis, Jay D. Iams, George Saade, Yoram Sorokin, Dwight J. Rouse, Sean C. Blackwell, Jorge E. Tolosa, M. Wallace, A. Northen, J. Grant, C. Colquitt, G. Mallett, M. Ramos-Brinson, A. Roy, L. Stein, P. Campbell, C. Collins, N. Jackson, M. Dinsmoor, J. Senka, K. Paychek, A. Peaceman, M. Talucci, M. Zylfijaj, Z. Reid, R. Leed, J. Benson, S. Forester, C. Kitto, S. Davis, M. Falk, C. Perez, K. Hill, A. Sowles, J. Postma, S. Alexander, G. Andersen, V. Scott, V. Morby, K. Jolley, J. Miller, B. Berg, K. Dorman, J. Mitchell, E. Kaluta, K. Clark, K. Spicer, S. Timlin, K. Wilson, L. Moseley, M. Santillan, J. Price, K. Buentipo, V. Bludau, T. Thomas, L. Fay, C. Melton, J. Kingsbery, R. Benezue, H. Simhan, M. Bickus, D. Fischer, T. Kamon, D. DeAngelis, B. Mercer, C. Milluzzi, W. Dalton, T. Dotson, P. McDonald, C. Brezine, A. McGrail, C. Latimer, L. Guzzo, F. Johnson, L. Gerwig, S. Fyffe, D. Loux, S. Frantz, D. Cline, S. Wylie, P. Shubert, J. Moss, A. Salazar, A. Acosta, G. Hankins, N. Hauff, L. Palmer, P. Lockhart, D. Driscoll, L. Wynn, C. Sudz, D. Dengate, C. Girard, S. Field, P. Breault, F. Smith, N. Annunziata, D. Allard, J. Silva, M. Gamage, J. Hunt, J. Tillinghast, N. Corcoran, M. Jimenez, F. Ortiz, P. Givens, B. Rech, C. Moran, M. Hutchinson, Z. Spears, C. Carreno, B. Heaps, G. Zamora, J. Seguin, M. Rincon, J. Snyder, C. Farrar, E. Lairson, C. Bonino, W. Smith, K. Beach, S. Van Dyke, S. Butcher, E. Thom, Y. Zhao, P. McGee, V. Momirova, R. Palugod, B. Reamer, M. Larsen, C. Spong, S. Tolivaisa, and J.P. VanDorsten
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neonatal intensive care unit ,Adolescent ,Term Birth ,Gestational Age ,Transient tachypnea of the newborn ,Article ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Intensive Care Units, Neonatal ,medicine ,Humans ,Labor, Induced ,030212 general & internal medicine ,Propensity Score ,Lung ,Hyperbilirubinemia ,030219 obstetrics & reproductive medicine ,Continuous Positive Airway Pressure ,Neonatal sepsis ,Cesarean Section ,business.industry ,Obstetrics ,Transient Tachypnea of the Newborn ,Infant, Newborn ,Obstetrics and Gynecology ,Gestational age ,Odds ratio ,Length of Stay ,Middle Aged ,Phototherapy ,medicine.disease ,Respiration, Artificial ,United States ,Logistic Models ,Elective Surgical Procedures ,Amniocentesis ,Apgar Score ,Female ,Apgar score ,Neonatal Sepsis ,business - Abstract
Background Studies of early-term birth after demonstrated fetal lung maturity show that respiratory and other outcomes are worse with early-term birth (370–386 weeks) even after demonstrated fetal lung maturity when compared with full-term birth (390–406 weeks). However, these studies included medically indicated births and are therefore potentially limited by confounding by the indication for delivery. Thus, the increase in adverse outcomes might be due to the indication for early-term birth rather than the early-term birth itself. Objective We examined the prevalence and risks of adverse neonatal outcomes associated with early-term birth after confirmed fetal lung maturity as compared with full-term birth in the absence of indications for early delivery. Study Design This is a secondary analysis of an observational study of births to 115,502 women in 25 hospitals in the United States from 2008 through 2011. Singleton nonanomalous births at 37–40 weeks with no identifiable indication for delivery were included; early-term births after positive fetal lung maturity testing were compared with full-term births. The primary outcome was a composite of death, ventilator for ≥2 days, continuous positive airway pressure, proven sepsis, pneumonia or meningitis, treated hypoglycemia, hyperbilirubinemia (phototherapy), and 5-minute Apgar Results In all, 48,137 births met inclusion criteria; the prevalence of fetal lung maturity testing in the absence of medical or obstetric indications for early delivery was 0.52% (n = 249). There were 180 (0.37%) early-term births after confirmed pulmonary maturity and 47,957 full-term births. Women in the former group were more likely to be non-Hispanic white, smoke, have received antenatal steroids, have induction, and have a cesarean. Risks of the composite (16.1% vs 5.4%; adjusted odds ratio, 3.2; 95% confidence interval, 2.1–4.8 from logistic regression) were more frequent with elective early-term birth. Propensity scores matching confirmed the increased primary composite in elective early-term births: adjusted odds ratios, 4.3 (95% confidence interval, 1.8–10.5) for 1:1 and 3.5 (95% confidence interval, 1.8–6.5) for 1:2 matching. Among components of the primary outcome, CPAP use and hyperbilirubinemia requiring phototherapy were significantly increased. Transient tachypnea of the newborn, neonatal intensive care unit admission, and prolonged neonatal intensive care unit stay (>2 days) were also increased with early-term birth. Conclusion Even with confirmed pulmonary maturity, early-term birth in the absence of medical or obstetric indications is associated with worse neonatal respiratory and hepatic outcomes compared with full-term birth, suggesting relative immaturity of these organ systems in early-term births.
- Published
- 2018
- Full Text
- View/download PDF
13. Social and ethnic differences in folic acid use preconception and during early pregnancy in the UK: effect on maternal folate status
- Author
-
Gail Rees, E. K. Dorman, Louise Brough, and Michael A. Crawford
- Subjects
Adult ,medicine.medical_specialty ,Population ,Ethnic group ,Medicine (miscellaneous) ,Social class ,Young Adult ,Folic Acid ,Pregnancy ,London ,medicine ,Humans ,Neural Tube Defects ,education ,Gynecology ,education.field_of_study ,Nutrition and Dietetics ,Neural tube defect ,Obstetrics ,business.industry ,Maternal effect ,Prenatal Care ,Health Status Disparities ,Maternal Nutritional Physiological Phenomena ,medicine.disease ,Social deprivation ,Socioeconomic Factors ,Dietary Supplements ,Vitamin B Complex ,Gestation ,Female ,Preconception Care ,business - Abstract
Background: The role of folate supplementation in preventing neural tube defects is well known; however, preconception supplement use continues to be low, especially amongst the socially disadvantaged. The present study explored periconception folic acid supplement use in a socially deprived, ethnically diverse population. Methods: Pregnant women (n = 402) in the first trimester of pregnancy were recruited in East London. Using a researcher led questionnaire, details were obtained regarding social class, ethnicity and folic acid use. Red cell folate levels were determined for 367 participants during the first trimester. Results: Although 76% of participants reported using folic acid supplements during the first trimester, only 12% started preconception and a further 17% started before neural tube closure. Mothers from higher social groups or with higher levels of education were more likely to use folic acid and started taking it earlier. Ethnic differences were also seen in preconception usage (Africans, 5%; West Indians, 8%; Asians, 12%; Caucasians, 19%; P = 0.038). Participants who took folic acid supplements had significantly higher mean (SD) red cell folate concentrations than those who took none [936 (*\1.6) and 579 (*\1.6) nmol L )1 , respectively; P < 0.001]. Conclusions: Folic acid supplement use preconception and prior to neural tube closure continues to be low, exhibiting both social and ethnic disparities.
- Published
- 2009
- Full Text
- View/download PDF
14. Failure of an ICD to Deliver Antitachycardia Therapy against Recurrent, Sustained Ventricular Tachycardia: What's the Mechanism?
- Author
-
Michael C, Willoughby, Evangelos, Diamantakos, Andrea K, Dorman, and Luis A, Pires
- Subjects
Equipment Failure Analysis ,Male ,Recurrence ,Therapy, Computer-Assisted ,Tachycardia, Ventricular ,Humans ,Equipment Failure ,Treatment Failure ,Middle Aged ,Defibrillators, Implantable - Published
- 2015
15. Does the presence of a condition-specific obstetric protocol lead to detectable improvements in pregnancy outcomes?
- Author
-
Jennifer L. Bailit, William A. Grobman, Paula McGee, Uma M. Reddy, Ronald J. Wapner, Michael W. Varner, John M. Thorp, Kenneth J. Leveno, Jay D. Iams, Alan T.N. Tita, George Saade, Yoram Sorokin, Dwight J. Rouse, Sean C. Blackwell, B. Mercer, C. Milluzzi, W. Dalton, T. Dotson, P. McDonald, C. Brezine, A. McGrail, G. Mallett, M. Ramos-Brinson, A. Roy, L. Stein, P. Campbell, C. Collins, N. Jackson, M. Dinsmoor, J. Senka, K. Paychek, A. Peaceman, M. Talucci, M. Zylfijaj, Z. Reid, R. Leed, J. Benson, S. Forester, C. Kitto, S. Davis, M. Falk, C. Perez, K. Hill, A. Sowles, J. Postma, S. Alexander, G. Andersen, V. Scott, V. Morby, K. Jolley, J. Miller, B. Berg, K. Dorman, J. Mitchell, E. Kaluta, K. Clark, K. Spicer, S. Timlin, K. Wilson, L. Moseley, M. Santillan, J. Price, K. Buentipo, V. Bludau, T. Thomas, L. Fay, C. Melton, J. Kingsbery, R. Benezue, S. Caritis, H. Simhan, M. Bickus, D. Fischer, T. Kamon, D. DeAngelis, P. Shubert, C. Latimer, L. Guzzo, F. Johnson, L. Gerwig, S. Fyffe, D. Loux, S. Frantz, D. Cline, S. Wylie, J. Iams, M. Wallace, A. Northen, J. Grant, C. Colquitt, J. Moss, A. Salazar, A. Acosta, G. Hankins, N. Hauff, L. Palmer, P. Lockhart, D. Driscoll, L. Wynn, C. Sudz, D. Dengate, C. Girard, S. Field, P. Breault, F. Smith, N. Annunziata, D. Allard, J. Silva, M. Gamage, J. Hunt, J. Tillinghast, N. Corcoran, M. Jimenez, F. Ortiz, P. Givens, B. Rech, C. Moran, M. Hutchinson, Z. Spears, C. Carreno, B. Heaps, G. Zamora, J. Tolosa, J. Seguin, M. Rincon, J. Snyder, C. Farrar, E. Lairson, C. Bonino, W. Smith, K. Beach, S. Van Dyke, S. Butcher, E. Thom, M. Rice, Y. Zhao, P. McGee, V. Momirova, R. Palugod, B. Reamer, M. Larsen, T. Williams, C. Spong, S. Tolivaisa, and J.P. Van Dorsten
- Subjects
Adult ,medicine.medical_specialty ,Article ,law.invention ,Shoulder dystocia ,Clinical Protocols ,Pre-Eclampsia ,law ,Pregnancy ,medicine ,Maternal hypertension ,Humans ,Intensive care medicine ,Lead (electronics) ,Pregnancy outcomes ,Protocol (science) ,Obstetrics ,business.industry ,Postpartum Hemorrhage ,Pregnancy Outcome ,Obstetrics and Gynecology ,Odds ratio ,General Medicine ,medicine.disease ,Intensive care unit ,Confidence interval ,Pregnancy Complications ,Female ,business ,Cohort study - Abstract
Objective We sought to evaluate whether the presence of condition-specific obstetric protocols within a hospital was associated with better maternal and neonatal outcomes. Study Design This was a cohort study of a random sample of deliveries performed at 25 hospitals over 3 years. Condition-specific protocols were collected from all hospitals and categorized independently by 2 authors. Data on maternal and neonatal outcomes, as well as data necessary for risk adjustment were collected. Risk-adjusted outcomes were compared according to whether the patient delivered in a hospital with condition-specific obstetric protocols at the time of delivery. Results Hemorrhage-specific protocols were not associated with a lower rate of postpartum hemorrhage or with fewer cases of estimated blood loss >1000 mL. Similarly, in the presence of a shoulder dystocia protocol, there were no differences in the frequency of shoulder dystocia or number of shoulder dystocia maneuvers used. Conversely, preeclampsia-specific protocols were associated with fewer intensive care unit admissions (odds ratio, 0.28; 95% confidence interval, 0.18–0.44) and fewer cases of severe maternal hypertension (odds ratio, 0.86; 95% confidence interval, 0.77–0.96). Conclusion The presence of condition-specific obstetric protocols was not consistently shown to be associated with improved risk-adjusted outcomes. Our study would suggest that the presence or absence of a protocol does not matter and regulations to require protocols are not fruitful.
- Published
- 2015
16. Impaired uteroplacental blood flow in pregnancies complicated by falciparum malaria
- Author
-
J. Mwendwa, Caroline Shulman, John Kingdom, Judith N. Bulmer, Kevin Marsh, N Peshu, and E. K. Dorman
- Subjects
medicine.medical_specialty ,Fetus ,Radiological and Ultrasound Technology ,Obstetrics ,Anemia ,business.industry ,Birth weight ,Obstetrics and Gynecology ,General Medicine ,Intervillous space ,medicine.disease ,Low birth weight ,Reproductive Medicine ,medicine.artery ,parasitic diseases ,medicine ,Gestation ,Radiology, Nuclear Medicine and imaging ,medicine.symptom ,Uterine artery ,business ,Malaria - Abstract
Objective In endemic areas, maternal malaria infection is usually asymptomatic. However, it is known that infected maternal erythrocytes sequester in the intervillous space of the placenta. There is a strong association between placental malaria infection and both low birth weight (LBW) and severe maternal anemia. We aimed to determine whether impaired uteroplacental blood flow might account for the low infant birth weight associated with maternal falciparum malaria infection. Methods This observational study was carried out during a large double-blind, randomized, controlled trial of an antimalarial drug intervention for primigravidae. Nine hundred and ninety-five women were recruited from the antenatal clinic at a district hospital on the Kenya coast and had at least one Doppler ultrasound scan. Uterine artery resistance index and the presence or absence of a diastolic notch were recorded. In the third trimester, blood was taken for hemoglobin and malaria film. Results Malaria infection at 32–35 weeks of gestation was associated with abnormal uterine artery flow velocity waveforms on the day of blood testing (relative risk (RR) 2.11, 95% confidence interval (CI) 1.24–3.59, P = 0.006). This association persisted after controlling for pre-eclampsia. Impaired uteroplacental blood flow in the women studied was also predictive of poor perinatal outcome, including low birth weight, preterm delivery and perinatal death. The risk of preterm delivery in women with histological evidence of past placental malaria infection was more than twice that of women without infection (RR 2.33, 95% CI 1.31–4.13, P = 0.004). Conclusions Uteroplacental hemodynamics are altered in the presence of maternal falciparum malaria infection. This may account for some of the excess of LBW babies observed in malaria endemic areas. Strategies that prevent or clear placental malaria may confer perinatal benefit through preservation of placental function. Copyright © 2002 ISUOG
- Published
- 2002
- Full Text
- View/download PDF
17. Evaluation of delivery options for second-stage events
- Author
-
Jennifer L. Bailit, William A. Grobman, Madeline Murguia Rice, Ronald J. Wapner, Uma M. Reddy, Michael W. Varner, John M. Thorp, Steve N. Caritis, Jay D. Iams, George Saade, Dwight J. Rouse, Jorge E. Tolosa, M. Talucci, M. Zylfijaj, Z. Reid, R. Leed, J. Benson, S. Forester, C. Kitto, S. Davis, M. Falk, C. Perez, K. Hill, A. Sowles, J. Postma, S. Alexander, G. Andersen, V. Scott, V. Morby, K. Jolley, J. Miller, B. Berg, K. Dorman, J. Mitchell, E. Kaluta, K. Clark, K. Spicer, S. Timlin, K. Wilson, K. Leveno, L. Moseley, M. Santillan, J. Price, K. Buentipo, V. Bludau, T. Thomas, L. Fay, C. Melton, J. Kingsbery, R. Benezue, H. Simhan, M. Bickus, D. Fischer, T. Kamon, D. DeAngelis, B. Mercer, C. Milluzzi, W. Dalton, T. Dotson, P. McDonald, C. Brezine, A. McGrail, C. Latimer, L. Guzzo, F. Johnson, L. Gerwig, S. Fyffe, D. Loux, S. Frantz, D. Cline, S. Wylie, J. Iams, A. Tita, M. Wallace, A. Northen, J. Grant, C. Colquitt, D. Rouse, W. Andrews, G. Mallett, M. Ramos-Brinson, A. Roy, L. Stein, P. Campbell, C. Collins, N. Jackson, M. Dinsmoor, J. Senka, K. Paychek, A. Peaceman, J. Moss, A. Salazar, A. Acosta, G. Hankins, Y. Sorokin, N. Hauff, L. Palmer, P. Lockhart, D. Driscoll, L. Wynn, C. Sudz, D. Dengate, C. Girard, S. Field, P. Breault, F. Smith, N. Annunziata, D. Allard, J. Silva, M. Gamage, J. Hunt, J. Tillinghast, N. Corcoran, M. Jimenez, S. Blackwell, F. Ortiz, P. Givens, B. Rech, C. Moran, M. Hutchinson, Z. Spears, C. Carreno, B. Heaps, G. Zamora, J. Seguin, M. Rincon, J. Snyder, C. Farrar, E. Lairson, C. Bonino, W. Smith, K. Beach, S. Van Dyke, S. Butcher, E. Thom, Y. Zhao, P. McGee, V. Momirova, R. Palugod, B. Reamer, M. Larsen, T. Williams, C. Swartz, V. Bhandaru, C. Spong, S. Tolivaisa, and J.P. VanDorsten
- Subjects
Adult ,medicine.medical_specialty ,Vacuum Extraction, Obstetrical ,Forceps ,Obstetrical Forceps ,Subgaleal hemorrhage ,Lacerations ,Article ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Labor Stage, Second ,Pregnancy ,medicine ,Humans ,030212 general & internal medicine ,reproductive and urinary physiology ,Fetal Station ,030219 obstetrics & reproductive medicine ,Cesarean Section ,Vaginal delivery ,business.industry ,Postpartum Hemorrhage ,Obstetrics and Gynecology ,Odds ratio ,Delivery, Obstetric ,medicine.disease ,United States ,Surgery ,Puerperal Infection ,Female ,business ,Cohort study - Abstract
Background Cesarean delivery in the second stage of labor is common, whereas the frequency of operative vaginal delivery has been declining. However, data comparing outcomes for attempted operative vaginal delivery vs cesarean in the second stage are scant. Previous studies that examine operative vaginal delivery have compared it to a baseline risk of complications from a spontaneous vaginal delivery and cesarean delivery. However, when a woman has a need for intervention in the second stage, spontaneous vaginal delivery is not an option she or the provider can choose. Thus, the appropriate clinical comparison is cesarean vs operative vaginal delivery. Objective Our objective was to compare outcomes by the first attempted operative delivery (vacuum, forceps vs cesarean delivery) in patients needing second-stage assistance at a fetal station of +2 or below. Study Design We conducted secondary analysis of an observational obstetric cohort in 25 academically affiliated US hospitals over a 3-year period. A subset of ≥37 weeks, nonanomalous, vertex, singletons, with no prior vaginal delivery who reached a station of +2 or below and underwent an attempt at an operative delivery were included. Indications included for operative delivery were: failure to descend, nonreassuring fetal status, labor dystocia, or maternal exhaustion. The primary outcomes included a composite neonatal outcome (death, fracture, length of stay ≥3 days beyond mother's, low Apgar, subgaleal hemorrhage, ventilator support, hypoxic encephalopathy, brachial plexus injury, facial nerve palsy) and individual maternal outcomes (postpartum hemorrhage, third- and fourth-degree tears [severe lacerations], and postpartum infection). Outcomes were examined by the 3 attempted modes of delivery. Odds ratios (OR) were calculated for primary outcomes adjusting for confounders. Final mode of delivery was quantified. Results In all, 2531 women met inclusion criteria. No difference in the neonatal composite outcome was observed between groups. Vacuum attempt was associated with the lowest frequency of maternal complications (postpartum infection 0.2% vs 0.9% forceps vs 5.3% cesarean, postpartum hemorrhage 1.4% vs 2.8% forceps vs 3.8% cesarean), except for severe lacerations (19.1% vs 33.8% forceps vs 0% cesarean). When confounders were taken into account, both forceps (OR, 0.16; 95% confidence interval, 0.05–0.49) and vacuum (OR, 0.04; 95% confidence interval, 0.01–0.17) were associated with a significantly lower odds of postpartum infection. The neonatal composite and postpartum hemorrhage were not significantly different between modes of attempted delivery. Cesarean occurred in 6.4% and 4.4% of attempted vacuum and forceps groups ( P = .04). Conclusion In patients needing second-stage delivery assistance with a station of +2 or below, attempted operative vaginal delivery was associated with a lower frequency of postpartum infection, but higher frequency of severe lacerations.
- Published
- 2016
- Full Text
- View/download PDF
18. Shaping Sea-Level Rise Adaptation Policy through Science: The North Carolina Sea Level Rise Risk Management Study
- Author
-
John K. Dorman, Adam Hosking, and Brian K. Batten
- Subjects
Engineering ,Cost–benefit analysis ,Sea level rise ,Flood myth ,business.industry ,Process (engineering) ,Environmental resource management ,State legislature ,business ,Adaptation (computer science) ,Hazard ,Environmental planning ,Risk management - Abstract
Sea level rise adaptation policy is often approached without adequate knowledge of the potential hazard and risk impacts, or lacks consideration of detailed benefit cost analysis of adaptation strategies. The North Carolina Sea Level Rise Risk Management Study seeks to establish a comprehensive framework to directly translate the projected consequences into adaptation policy, with full realization of the potential long-term benefits. The study provides for detailed numerical quantification of the response of coastal and flood dynamics to sea level rise, and impact of those hazards on system-wide resources. A key objective of the effort is to inform the state legislature of the potential risk to sea level rise and the projected short- and long-term benefits of adaptation measures. We also seek to provide a transferable process framework and documenting lessons learned for conducting similar future assessments.
- Published
- 2011
- Full Text
- View/download PDF
19. Vertebroplasty of the C2 vertebral body and dens using an anterior cervical approach: technical case report
- Author
-
John K Dorman
- Subjects
medicine.medical_specialty ,Cervical approach ,Biopsy ,medicine ,Humans ,Neck pain ,Vertebroplasty ,Neck Pain ,medicine.diagnostic_test ,business.industry ,Bone Cements ,Magnetic resonance imaging ,Middle Aged ,Magnetic Resonance Imaging ,Surgery ,Vertebral body ,medicine.anatomical_structure ,Cervical Vertebrae ,Female ,Neurology (clinical) ,Anterior approach ,medicine.symptom ,Presentation (obstetrics) ,business ,Tomography, X-Ray Computed ,Cervical vertebrae - Abstract
BACKGROUND AND IMPORTANCE: This article is the first description of an anterior approach for a biopsy and vertebroplasty of the C2 body and dens. CLINICAL PRESENTATION: A 52-year-old woman presented with a 9-month history of neck pain and a destructive lesion of the dens. The patient was treated with pain medication as well as steroid injections without relief of her pain. A biopsy and vertebroplasty of the C2 body and dens was performed using an anterior cervical approach. CONCLUSION: This report describes the first vertebroplasty of C2 using an open anterior cervical approach.
- Published
- 2010
20. Effect of multiple-micronutrient supplementation on maternal nutrient status, infant birth weight and gestational age at birth in a low-income, multi-ethnic population
- Author
-
Gail Rees, Michael A. Crawford, Edgar K. Dorman, R. Hugh Morton, and Louise Brough
- Subjects
Adult ,medicine.medical_specialty ,Pediatrics ,Erythrocytes ,Birth weight ,Population ,Medicine (miscellaneous) ,Nutritional Status ,Gestational Age ,Hemoglobins ,Young Adult ,Folic Acid ,Double-Blind Method ,Pregnancy ,Vitamin D and neurology ,medicine ,Ethnicity ,Prevalence ,Birth Weight ,Humans ,Micronutrients ,Vitamin D ,education ,Poverty ,education.field_of_study ,Nutrition and Dietetics ,Fetal Growth Retardation ,Obstetrics ,business.industry ,Incidence (epidemiology) ,Infant, Newborn ,Pregnancy Outcome ,Gestational age ,Maternal Nutritional Physiological Phenomena ,medicine.disease ,Micronutrient ,United Kingdom ,Intention to Treat Analysis ,Pregnancy Complications ,Hematocrit ,Dietary Supplements ,Ferritins ,Infant, Small for Gestational Age ,Gestation ,Female ,business ,Deficiency Diseases - Abstract
Poor nutrient intake during pregnancy can adversely affect both infant and maternal health. The aim was to investigate the efficacy of multiple-micronutrient supplementation during pregnancy in a socially deprived population in the developed world. We conducted a randomised, double-blind, placebo-controlled trial of multiple-micronutrient supplementation including 20 mg Fe and 400 μg folic acid, from the first trimester of pregnancy in 402 mothers, in East London, UK. Nutrient status was measured at recruitment, and at 26 and 34 weeks of gestation. Infants were weighed at birth. At recruitment the prevalence of anaemia was 13 %, vitamin D insufficiency 72 %, thiamin deficiency 12 % and folate deficiency 5 %, with no differences between groups. Only 39 % of women completed the study; rates of non-compliance were similar in both groups. Intention-to-treat analysis showed that participants receiving treatment had higher mean Hb at 26 weeks of gestation (110 (sd10)v.108 (sd10) g/l;P = 0·041) and 34 weeks of gestation (113 (sd12)v.109 (sd10) g/l;P = 0·003) and packed cell volume concentrations at 26 weeks of gestation (0·330 (sd0·025)v.0·323 (sd0·026) l/l;P = 0·011) and 34 weeks of gestation (0·338 (sd0·029)v.0·330 (sd0·028) l/l;P = 0·014) compared with controls. Analysis of compliant women showed supplemented women had higher median concentrations of serum ferritin, erythrocyte folate and 25-hydroxyvitamin D later in gestation than controls. In the compliant subset (n149), placebo mothers had more small-for-gestational age (SGA) infants (eight SGAv.thirteen;P = 0·042) than treatment mothers. Baseline micronutrient deficiencies were common; the multiple-micronutrient supplement was well-tolerated and improved nutrient status. Multiple-micronutrient supplements from early pregnancy may be beneficial and larger studies are required to assess impact on birth outcomes and infant development.
- Published
- 2010
21. Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya
- Author
-
Judith N. Bulmer, Ken Kawuondo, Kevin Marsh, Caroline Shulman, E. K. Dorman, Phillippa M. Cumberland, Felicity T. Cutts, and P.A. Chris Maple
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Biopsy ,Placenta ,Population ,Plasmodium falciparum ,Enzyme-Linked Immunosorbent Assay ,HIV Infections ,Tetanus Antitoxin ,complex mixtures ,Pregnancy ,medicine ,Tetanus Toxoid ,Immunology and Allergy ,Animals ,Humans ,Malaria, Falciparum ,Pregnancy Complications, Infectious ,education ,education.field_of_study ,Tetanus ,biology ,Obstetrics ,business.industry ,Vaccination ,Toxoid ,Infant, Newborn ,HIV ,medicine.disease ,Fetal Blood ,Antibodies, Bacterial ,Kenya ,Neonatal tetanus ,Infectious Diseases ,Immunology ,biology.protein ,Female ,Antibody ,business ,Immunity, Maternally-Acquired ,Malaria - Abstract
BACKGROUND: In clinical trials, maternal tetanus toxoid (TT) vaccination is effective in protecting newborns against tetanus infection, but inadequate placental transfer of tetanus antibodies may contribute to lower-than-expected rates of protection in routine practice. We studied the effect of placental malaria and maternal human immunodeficiency virus (HIV) infection on placental transfer of antibodies to tetanus. METHODS: A total of 704 maternal-cord paired serum samples were tested by ELISA for antibodies to tetanus. The HIV status of all women was determined by an immunoglobulin G antibody-capture particle-adherence test, and placental malaria was determined by placental biopsy. Maternal history of TT vaccination was recorded. RESULTS: Tetanus antibody levels were reduced by 52% (95% confidence interval [CI], 30%-67%) in newborns of HIV-infected women and by 48% (95% CI, 26%-62%) in newborns whose mothers had active-chronic or past placental malaria. Thirty-seven mothers (5.3%) and 55 newborns (7.8%) had tetanus antibody levels
- Published
- 2006
22. Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples
- Author
-
Caroline Shulman, Simon Cousens, Susana Scott, Felicity T. Cutts, David Brown, Ken Kawuondo, Phillippa M. Cumberland, E. K. Dorman, Judith N. Bulmer, Bernard J. Cohen, and Kevin Marsh
- Subjects
Adult ,Rural Population ,Adolescent ,Placenta ,HIV Infections ,Antibodies, Viral ,Measles ,Acquired immunodeficiency syndrome (AIDS) ,Immunity ,Pregnancy ,Risk Factors ,medicine ,Immunology and Allergy ,Humans ,Pregnancy Complications, Infectious ,biology ,business.industry ,Infant, Newborn ,Gestational age ,medicine.disease ,Fetal Blood ,Kenya ,Malaria ,Infectious Diseases ,Immunology ,biology.protein ,Female ,Viral disease ,Antibody ,business ,Immunity, Maternally-Acquired - Abstract
INTRODUCTION: Young infants are protected from measles infection by maternal measles antibodies. The level of these antibodies at birth depends on the level of antibodies in the mother and the extent of placental transfer. We investigated predictors of levels of measles antibodies in newborns in rural Kenya. METHODS: A total of 747 paired maternal-cord serum samples (91 from human immunodeficiency virus [HIV]-infected and 656 from HIV-uninfected mothers) were tested for measles immunoglobulin G antibodies. Placental malaria infection was determined by biopsy. Data on pregnancy history, gestational age, and anthropometric and socioeconomic status were collected. RESULTS: Infants born to HIV-infected mothers were more likely (odds ratio, 4.6 [95% confidence interval {CI}, 2.2-9.7]) to be seronegative and had 35.1% (95% CI, 9.8%-53.2%) lower levels of measles antibodies than did those born to HIV-uninfected mothers. Preterm delivery, early maternal age, and ethnic group were also associated with reduced levels of measles antibodies. There was little evidence that placental malaria infection was associated with levels of measles antibodies in newborns. CONCLUSION: Our results suggest that maternal HIV infection may reduce levels of measles antibodies in newborns. Low levels of measles antibodies at birth render children susceptible to measles infection at an early age. This is of concern in sub-Saharan African countries, where not only is the prevalence of HIV high, but measles is the cause of much morbidity and mortality.
- Published
- 2004
23. Importance and prevention of malaria in pregnancy
- Author
-
Caroline Shulman and E. K. Dorman
- Subjects
Pediatrics ,medicine.medical_specialty ,Endemic Diseases ,HIV Infections ,Asymptomatic ,Insect Control ,Antimalarials ,Obstetric Labor, Premature ,Pregnancy ,Poverty Areas ,Prenatal Diagnosis ,parasitic diseases ,medicine ,Humans ,Malaria, Falciparum ,Pregnancy Complications, Infectious ,Travel ,Fetal Growth Retardation ,biology ,business.industry ,Public Health, Environmental and Occupational Health ,Infant, Newborn ,Bedding and Linens ,Plasmodium falciparum ,Anemia ,General Medicine ,Infant, Low Birth Weight ,medicine.disease ,biology.organism_classification ,Low birth weight ,Infectious Diseases ,Maternal Mortality ,Cerebral Malaria ,Pregnancy Complications, Parasitic ,Immunology ,Chemoprophylaxis ,Mosquito net ,Parasitology ,Female ,medicine.symptom ,business ,Malaria - Abstract
Malaria in pregnancy is one of the most important preventable causes of low birthweight deliveries worldwide. It is also a major cause of severe maternal anaemia contributing to maternal mortality. It is estimated that 40% of the world's pregnant women are exposed to malaria infection during pregnancy. The clinical features of Plasmodium falciparum malaria in pregnancy depend to a large extent on the immune status of the woman, which in turn is determined by her previous exposure to malaria. In pregnant women with little or no pre-existing immunity, such as women from non-endemic areas or travellers to malarious areas, infection is associated with high risks of severe disease with maternal and perinatal mortality. Women are at particular risk of cerebral malaria, hypoglycaemia, pulmonary oedema and severe haemolytic anaemia. Fetal and perinatal loss has been documented to be as high as 60-70% in non-immune women with malaria. Adults who are long-term residents of areas of moderate or high malaria transmission, including large parts of sub-Saharan Africa, usually have a high level of immunity to malaria. Infection is frequently asymptomatic and severe disease is uncommon. During pregnancy this immunity to malaria is altered. Infection is still frequently asymptomatic, so may go unsuspected and undetected, but is associated with placental parasitization. Malaria in pregnancy is a common cause of severe maternal anaemia and low birthweight babies, these complications being more common in primigravidae than multigravidae. Preventative strategies include regular chemoprophylaxis, intermittent preventative treatment with antimalarials and insecticide-treated bednets.
- Published
- 2003
24. LEAH: an introduction to behavioral abstraction and co-simulation using Perl and Verilog
- Author
-
K. Dorman, E. Mednick, and B. Gelinas
- Subjects
Unix ,Emulation ,Hardware_MEMORYSTRUCTURES ,Computer science ,Hardware description language ,Pentium ,Multiprocessing ,ComputerSystemsOrganization_PROCESSORARCHITECTURES ,computer.software_genre ,Scripting language ,Operating system ,Verilog ,Perl ,computer ,computer.programming_language - Abstract
The paper introduces LEAH, (L2 Emulation Apparatus at a High level), which is a Perl based abstraction of multiprocessor Intel Pentium Pro Processor systems, including processors, memory and I/O subsystems. LEAH is connected to a Verilog simulation through a Unix socket and PLI. Using Perl as its programming base, LEAH abstracts behavior at a high level. Multiple scripts based on the rich facilities of Perl are executed by abstract processors in a multitasking environment. Internal events, such as a cache miss, trigger the use of the Unix socket interface to a Pentium Pro bus interface in the Verilog simulator.
- Published
- 2002
- Full Text
- View/download PDF
25. An endothelial nitric oxide synthase gene polymorphism is associated with preeclampsia
- Author
-
C B, Tempfer, K, Dorman, R L, Deter, W E, O'Brien, and A R, Gregg
- Subjects
Adult ,Polymorphism, Genetic ,Adolescent ,Nitric Oxide Synthase Type III ,Pre-Eclampsia ,Pregnancy ,Humans ,Female ,Nitric Oxide Synthase ,Polymerase Chain Reaction - Abstract
We sought to test the hypothesis that a polymorphism of the endothelial nitric oxide synthase gene (NOS3) is associated with preeclampsia.We collected and performed polymerase chain reaction (PCR) on genomic DNA from pregnant patients with and without preeclampsia. Patient history and clinical course were evaluated.Frequency of the intron 4 polymorphism of NOS3 (designated allele A) among patients with preeclampsia compared with controls. Clinical features of patients with preeclampsia and the A allele compared with those patients with preeclampsia who did not have the A allele.The frequency of the A allele was 0.10 among controls versus 0.39 among patients with preeclampsia (p0.01). The odds ratio of developing preeclampsia when at least one A allele was present was 6.5 [95% confidence interval (CI): 2.1-19.7]. After adjusting for ethnic variation, the odds ratio increased to 7.2 (95% CI: 2.0-25.5). Among patients with preeclampsia, systolic blood pressure at the time of admission was higher for patients with at least one A allele compared with patients homozygous for the B allele (168 versus 156 mm Hg; p = 0.03), independent of gestational age (p = 0.01).These data provide evidence for an association between NOS3 and preeclampsia. In defined ethnic groups, this NOS3 may offer predictive information regarding the subsequent development of preeclampsia and its clinical course.
- Published
- 2002
26. Impaired uteroplacental blood flow in pregnancies complicated by falciparum malaria
- Author
-
E K, Dorman, C E, Shulman, J, Kingdom, J N, Bulmer, J, Mwendwa, N, Peshu, and K, Marsh
- Subjects
Adult ,Adolescent ,Double-Blind Method ,Pregnancy ,Pregnancy Complications, Parasitic ,Pregnancy Outcome ,Humans ,Female ,Placental Circulation ,Ultrasonography, Doppler ,Malaria, Falciparum ,Blood Flow Velocity ,Ultrasonography, Prenatal - Abstract
In endemic areas, maternal malaria infection is usually asymptomatic. However, it is known that infected maternal erythrocytes sequester in the intervillous space of the placenta. There is a strong association between placental malaria infection and both low birth weight (LBW) and severe maternal anemia. We aimed to determine whether impaired uteroplacental blood flow might account for the low infant birth weight associated with maternal falciparum malaria infection.This observational study was carried out during a large double-blind, randomized, controlled trial of an antimalarial drug intervention for primigravidae. Nine hundred and ninety-five women were recruited from the antenatal clinic at a district hospital on the Kenya coast and had at least one Doppler ultrasound scan. Uterine artery resistance index and the presence or absence of a diastolic notch were recorded. In the third trimester, blood was taken for hemoglobin and malaria film.Malaria infection at 32-35 weeks of gestation was associated with abnormal uterine artery flow velocity waveforms on the day of blood testing (relative risk (RR) 2.11, 95% confidence interval (CI) 1.24-3.59, P = 0.006). This association persisted after controlling for pre-eclampsia. Impaired uteroplacental blood flow in the women studied was also predictive of poor perinatal outcome, including low birth weight, preterm delivery and perinatal death. The risk of preterm delivery in women with histological evidence of past placental malaria infection was more than twice that of women without infection (RR 2.33, 95% CI 1.31-4.13, P = 0.004).Uteroplacental hemodynamics are altered in the presence of maternal falciparum malaria infection. This may account for some of the excess of LBW babies observed in malaria endemic areas. Strategies that prevent or clear placental malaria may confer perinatal benefit through preservation of placental function.
- Published
- 2002
27. Malaria in pregnancy: adverse effects on haemoglobin levels and birthweight in primigravidae and multigravidae
- Author
-
Kevin Marsh, E. K. Dorman, Caroline Shulman, N Peshu, Tom Marshall, Judith N. Bulmer, and Felicity T. Cutts
- Subjects
Adult ,medicine.medical_specialty ,Anemia, Hemolytic ,Adolescent ,Anemia ,Birth weight ,Population ,Hemoglobins ,Pregnancy ,Surveys and Questionnaires ,parasitic diseases ,medicine ,Prevalence ,Birth Weight ,Humans ,Malaria, Falciparum ,Adverse effect ,education ,reproductive and urinary physiology ,education.field_of_study ,Obstetrics ,business.industry ,Pregnancy Complications, Hematologic ,Public Health, Environmental and Occupational Health ,Infant, Newborn ,medicine.disease ,Kenya ,Low birth weight ,Parity ,Infectious Diseases ,Pregnancy Complications, Parasitic ,Gestation ,Parasitology ,Female ,medicine.symptom ,business ,Malaria - Abstract
BACKGROUND: In areas of endemic transmission, malaria in pregnancy is associated with severe maternal anaemia and low birthweight babies. The prevalence of infection is highest in primigravidae (PG), and hence control efforts are usually geared towards this high risk group. Using a sensitive measure of placental infection, we investigated the relationship between active-acute, active-chronic and past placental infection with maternal anaemia and low birthweight in women of all gravidities. METHODS: Between January 1996 and July 1997, 912 women delivering in Kilifi District Hospital, Kenya, were recruited. Haemoglobin and peripheral malaria slides were taken prior to delivery, placental biopsies and smears were taken at the time of delivery and birthweight and maternal height and weight were measured soon after birth. Information was obtained on socio-economic and educational status. The association between placental malaria, severe anaemia and low birthweight was investigated for women of different gravidities. FINDINGS: By placental histology, the prevalence of active or past malaria in all gravidities was high, ranging from 64% in PG to 30% in gravidities 5 and above. In gravidities 1-4, active malaria infection was associated with severe maternal anaemia, adjusted OR 2.21 (95% CI 1.36, 3.61). There was a significant interaction between chronic or past malaria and severe anaemia in their effects on birthweight, whereby the risk of low birthweight was very high in women with both chronic or past placental malaria and severe anaemia: OR 4.53 (1.19, 17.2) in PG; 13.5 (4.57, 40) in gravidities 2-4. INTERPRETATION: In this area of moderate malaria transmission, women of all parities have substantially increased risk of low birthweight and severe anaemia as a result of malaria infection in pregnancy. The risk of low birthweight is likely to be particularly high in areas with a high prevalence of severe anaemia.
- Published
- 2001
28. 341. Implementation of a Negotiated Consent Agreement Between the United States Environmental Protection Agency (USEPA) and the Refractory Ceramic Fiber Coalition (RCFC) to Collect Airborne Fiber Exposure Data
- Author
-
E. Casey, K. Dorman, and J. Treadway
- Subjects
Engineering ,Fiber (mathematics) ,business.industry ,Agency (sociology) ,Forensic engineering ,business ,Environmental planning ,Exposure data - Published
- 1999
- Full Text
- View/download PDF
29. A community randomized controlled trial of insecticide-treated bednets for the prevention of malaria and anaemia among primigravid women on the Kenyan coast
- Author
-
C E, Shulman, E K, Dorman, A O, Talisuna, B S, Lowe, C, Nevill, R W, Snow, H, Jilo, N, Peshu, J N, Bulmer, S, Graham, and K, Marsh
- Subjects
Risk ,Insecticides ,Pregnancy ,Pregnancy Complications, Parasitic ,Pregnancy Complications, Hematologic ,Bedding and Linens ,Humans ,Anemia ,Female ,Kenya ,Malaria - Abstract
The effectiveness of insecticide-treated bednets (ITBN) in preventing malaria and anaemia among primigravidae living in Kilifi District, Kenya, was assessed by a randomized controlled trial between September 1994 and November 1995. All residents within 28 community clusters received ITBN in July 1993, whilst residents of another 28 clusters served as contemporaneous controls. All resident primigravid women with singleton pregnancies attending antenatal care at Kilifi District Hospital were eligible for recruitment. 503 primigravidae were recruited. 91.4% were anaemic antenatally (Hb11 g/dl): 91.0% from the intervention arm and 92.0% from the control arm. Severe anaemia (Hb7 g/dl) was found among 15.1% of intervention women and 20.1% of control women (P = 0.28). No significant differences were observed in reports of febrile illness or the presence of chloroquine in the serum or peripheral parasitaemia during the third trimester between the two groups. In the women delivering in hospital (n = 130), there was no association between placental malaria infection and the intervention: 77.4% of placentas from control women had evidence of past or active infection, compared with 72.0% of placentas from intervention women (P = 0.76). Similarly, in the women delivering in hospital, ITBN did not improve birth weight, and there were no differences in perinatal mortality between the two study groups. Despite ITBN having a great impact on paediatric severe malaria and mortality in this transmission setting, there was very little impact of ITBN on the morbidity associated with malaria infection in primigravidae. Alternative strategies are required to tackle this continued public health problem for pregnant women living in endemic areas similar to the Kenyan Coast.
- Published
- 1998
30. Critical care obstetrics: experts' round table discussion
- Author
-
D A, Austin, R, Bashore, M E, Burke, J, Daddario, K, Dorman, C J, Harvey, M C, Sisson, and N H, Troiano
- Subjects
Critical Care ,Obstetric Nursing ,Humans ,Forecasting ,Specialties, Nursing - Abstract
A panel of leading experts in critical care obstetric (CCOB) nursing met to discuss the specialty and its future, the impact of changes in the health care system, educational opportunities to learn and update CCOB nursing, formation and use of standards for the specialty, patient placement (dedicated obstetric intensive care units [OB ICU], labor and delivery intensive care units [LD ICU], regular intensive care units [ICU]), patient populations, and interactions and working relationships with the physicians who care for CCOB patients (perinatologists, obstetricians, internists, obstetric medicine specialists, anesthesiologists, other subspecialists). The topics for discussion were chosen by Carol J. Harvey, RNC, MS, who acted as moderator and Mary Ellen Burke, RN, MS, coordinated the publication of the discussion.
- Published
- 1994
31. Mechanical ventilation during pregnancy
- Author
-
N H, Troiano and K, Dorman
- Subjects
Pregnancy Complications ,Critical Care ,Pregnancy ,Humans ,Female ,Respiration, Artificial - Abstract
Mechanical ventilatory support is a significant component in the delivery of critical care. With increasing frequency, obstetric critical care nurses face the challenge of caring for women who require mechanical ventilation during pregnancy. It is important that those caring for such patients understand fundamental principles of mechanical ventilation, associated complications, and specific nursing care measures.
- Published
- 1992
32. Malaria as a cause of severe anaemia in pregnancy
- Author
-
Caroline Shulman, Judith N. Bulmer, and E. K. Dorman
- Subjects
Pregnancy ,Pediatrics ,medicine.medical_specialty ,business.industry ,Pregnancy Complications, Hematologic ,Anemia ,General Medicine ,medicine.disease ,Kenya ,Malaria ,medicine ,Humans ,Female ,Pregnancy Complications, Infectious ,business ,Severe anaemia - Published
- 2002
- Full Text
- View/download PDF
33. Clinical picture of atypical anorexia nervosa associated with hypothalamic tumor
- Author
-
J H White, Patrick J. Kelly, and K Dorman
- Subjects
Male ,Anorexia Nervosa ,Adolescent ,Brain Neoplasms ,business.industry ,Hypothalamus ,Physiology ,Child Behavior Disorders ,Glioma ,Psychiatry and Mental health ,Humans ,Medicine ,Atypical anorexia nervosa ,business ,Stress, Psychological - Published
- 1977
- Full Text
- View/download PDF
34. A Plan for Teaching Arithmetic in the Commercial Course of the High School
- Author
-
Allison K. Dorman
- Subjects
Computer science ,Mathematics education ,Plan (drawing) ,Education ,Course (navigation) - Published
- 1907
- Full Text
- View/download PDF
35. Pharmacokinetics of the acyclureidopenicillins piperacillin and mezlocillin in the postpartum patient
- Author
-
S Feldman, K. Dorman, Sebastian Faro, David B. Cotton, Mark G. Martens, and G D Riddle
- Subjects
medicine.drug_class ,Antibiotics ,Methicillin ,Pharmacokinetics ,Pregnancy ,medicine ,polycyclic compounds ,Humans ,Pharmacology (medical) ,Chromatography, High Pressure Liquid ,Antibacterial agent ,Pharmacology ,Piperacillin ,Mezlocillin ,Mezlocilline ,business.industry ,Postpartum Period ,medicine.disease ,Infectious Diseases ,Anesthesia ,Female ,business ,Postpartum period ,medicine.drug ,Research Article - Abstract
The postpartum patient experiences numerous physiologic alterations, which may affect the pharmacokinetics of certain drugs. Six patients received either piperacillin or mezlocillin intravenously immediately after delivery. Serum half-life and clearance were, respectively, 82.4 min and 202 +/- 105 ml/min for mezlocillin and 32.9 min and 456 +/- 88 ml/min for piperacillin. The data revealed that mezlocillin and piperacillin have significantly different pharmacokinetic reactions in the postpartum patient at the doses used.
- Published
- 1987
36. Binocular versus monocular acuity in a patient with latent nystagmus
- Author
-
K, Dorman
- Subjects
Adult ,Male ,Strabismus ,Depth Perception ,Eyeglasses ,Adolescent ,Visual Acuity ,Humans ,Amblyopia ,Child ,Refractive Errors ,Nystagmus, Pathologic - Abstract
This is a case of latent nystagmus with a significant improvement in acuity with both eyes open rather than with either eye alone. If this patient's visual acuity was tested only O.D. alone and O.S. alone, the best visual acuity obtainable would have been 20/60. This might have had serious implications for A.F.'s work since a minimum visual acuity of 20/40 is needed to keep a driver's license in New York State. Since binocular acuity was 20/20, I assured him that driving is safe.
- Published
- 1982
37. Ocular Manifestations of Leprosy
- Author
-
Jane E. K. Dorman
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Adolescent ,Eye Diseases ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Dermatology ,Nepal ,Leprosy ,medicine ,Humans ,Female ,Child ,business ,Aged - Published
- 1973
- Full Text
- View/download PDF
38. THE EFFECT OF THREE PREOPERATIVE FLUID REGIMENS ON PERIPARTUM COLLOID OSMOTIC PRESSURE CHANGES
- Author
-
D. Cotton, K. Dorman, T. H. Joyce, Stephen Longmire, B. S. Skjonsby, and M. M. Jones
- Subjects
Oncotic pressure ,Anesthesiology and Pain Medicine ,business.industry ,Anesthesia ,Medicine ,business - Published
- 1985
- Full Text
- View/download PDF
39. Experience of Intimate Partner Violence-Related Head Trauma and Its Association With Posttraumatic Stress Disorder and Depression Symptoms Among Community Dwelling Women and Men.
- Author
-
Jain D, Esopenko C, Dorman K, Gurrapu S, and Marshall AD
- Abstract
Individuals who experience intimate partner violence (IPV) often report posttraumatic stress disorder (PTSD) and depressive symptoms and IPV-related head trauma (IPV-HT), which can also affect mental health. We aimed to estimate rates of IPV-HT and examine the unique associations of IPV, HT, and IPV-HT with PTSD and depression symptom severity in a community-based sample of cohabitating couples. A total of 413 participants (216 women, 1 non-binary) self-reported lifetime history of HT and physical IPV. Chi-square analyses and Fisher's exact tests were used to compare the proportion of women and men who reported IPV-HT. Kruskal-Wallis tests with Dunn's post-hoc testing and Bonferroni correction were used to compare symptom severity across five groups: (a) IPV-HT, (b) non-IPV-related HT (Other HT) with exposure to physical IPV (IPV-Other HT), (c) Other HT without exposure to physical IPV (No IPV-Other HT), (d) no exposure to HT with exposure to physical IPV (IPV-No HT), and (e) no exposure to HT without exposure to physical IPV (No IPV-No HT). A greater proportion of women than men reported IPV-HT from a fight or being strangled (fight: 50.0% vs. 3.6%, p < .001; Strangulation: 74.1% vs. 3.8%, p < .001). The IPV-HT and IPV-Other HT groups endorsed greater PTSD and depression symptom severity compared to all individuals with no history of physical IPV, regardless of HT exposure (IPV-No HT and IPV-Other HT groups). No differences in symptom severity between the IPV-HT and the other IPV groups (No HT and Other HT) were found. These results suggest that PTSD and depression symptom severity may be driven by experiencing physical IPV, with some exacerbation due to experiencing HT of any etiology. Future work seeking to examine the effects of IPV-HT on PTSD and depression symptom severity should consider any history of physical IPV and any additional HT exposures., Competing Interests: Declaration of Conflicting InterestsThe authors declared no potential conflicts of interests with respect to the authorship and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
40. Redo-TAVI with the SAPIEN 3 valve in degenerated calcified CoreValve/Evolut explants.
- Author
-
Meier D, Nigade A, Lai A, Dorman K, Gill H, Javani S, Akodad M, Wood DA, Rogers T, Puri R, Allen KB, Chhatriwalla AK, Reardon MJ, Tang GHL, Bapat VN, Webb JG, Fukuhara S, and Sellers SL
- Subjects
- Humans, Calcinosis surgery, Calcinosis physiopathology, Prosthesis Design, Female, Aged, Prosthesis Failure, Male, Treatment Outcome, Transcatheter Aortic Valve Replacement instrumentation, Transcatheter Aortic Valve Replacement methods, Heart Valve Prosthesis, Aortic Valve surgery, Aortic Valve diagnostic imaging, Aortic Valve physiopathology, Aortic Valve pathology, Aortic Valve Stenosis surgery, Aortic Valve Stenosis physiopathology
- Abstract
Background: Redo-transcatheter aortic valve implantation (TAVI) is the treatment of choice for failed transcatheter aortic valves. Currently, implantation of a SAPIEN 3 (S3) is indicated for redo-TAVI in degenerated CoreValve/Evolut (CV/EV) transcatheter aortic valves (TAVs) but is not well understood., Aims: We aimed to evaluate S3 function following implantation in explanted calcified CV/EV TAVs and to assess the impact of CV/EV pathology on redo-TAVI outcomes., Methods: Ex vivo hydrodynamic testing was performed per the International Organization for Standardization (ISO) 5840-3 standard on 4 S3 TAVs implanted at node 5 in calcified CV/EV explants. The mean gradient (MG), effective orifice area (EOA), peak velocity, regurgitant fraction (RF), geometric orifice area (GOA), leaflet overhang, leaflet pinwheeling, neoskirt height, and frame deformation were evaluated., Results: CV/EV explants were calcified and stenotic. Following S3 implantation, the MG and peak velocity decreased. As per the ISO standard, all S3 implants showed adequate EOA, and 3 out of 4 had an RF within the accepted value (<20%). CV/EV leaflet overhang ranged from 25-37%. Calcified leaflets remained stationary throughout the cardiac cycle (difference <9%) and were not pinned in a manner that constrained S3 systolic flow or appeared to prevent selective frame cannulation. The downstream CV/EV GOA was larger than the upstream S3 GOA during systole. S3 frame underexpansion was seen, resulting in leaflet pinwheeling (range 13-30%). Above the neoskirt, calcium protrusion was observed in contact with the S3 leaflets., Conclusions: S3 implantation at node 5 in calcified CV/EV valves resulted in satisfactory hydrodynamic performance in most configurations tested with stable leaflet overhang throughout the cardiac cycle. The long-term implications of S3 underexpansion, leaflet pinwheeling, and calcium protrusion require future studies.
- Published
- 2024
- Full Text
- View/download PDF
41. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
- Author
-
Dorman K, Boeck S, Caca K, Reichert M, Ettrich TJ, Oettle H, Waidmann O, Modest DP, Müller L, Michl P, Kanzler S, Pink D, Reinacher-Schick A, Geißler M, Pelz H, Kunzmann V, Held S, Schichtl T, Heinemann V, and Kullmann F
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Induction Chemotherapy methods, Drug Administration Schedule, Gemcitabine, Deoxycytidine analogs & derivatives, Deoxycytidine administration & dosage, Deoxycytidine therapeutic use, Deoxycytidine adverse effects, Paclitaxel administration & dosage, Paclitaxel adverse effects, Paclitaxel therapeutic use, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Albumins administration & dosage, Albumins adverse effects, Albumins therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal pathology
- Abstract
Background: A standardised dose-reduction strategy has not been established for the widely used gemcitabine plus nab-paclitaxel regimen in patients with metastatic pancreatic ductal adenocarcinoma. We aimed to investigate the efficacy and tolerability of alternating treatment cycles of nab-paclitaxel-gemcitabine combination therapy and gemcitabine alone versus continuous treatment with the nab-paclitaxel-gemcitabine combination., Methods: ALPACA was a randomised, open-label, phase 2 trial conducted at 29 study centres across Germany. Patients aged 18 years or older with a histologically or cytologically confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma who had not been previously treated for advanced disease were enrolled. After an induction phase with three cycles of nab-paclitaxel-gemcitabine combination therapy (nab-paclitaxel 125 mg/m
2 and gemcitabine 1000 mg/m2 administered intravenously on days 1, 8, and 15 of each 28-day cycle), patients were randomly assigned (1:1) by stratified permuted block randomisation either to continue treatment with standard nab-paclitaxel-gemcitabine or to receive alternating cycles of nab-paclitaxel-gemcitabine and gemcitabine alone. Patients and investigators were not masked to treatment allocation. Randomisation was done centrally by the study statistician using a computer-generated randomisation list, and was stratified by Karnofsky Performance Status and presence of liver metastases. The primary endpoint was the derivation of an unbiased point estimate and an associated confidence interval with a confidence coefficient of 80% for the hazard ratio (HR) for overall survival after randomisation, without testing a specific hypothesis, analysed by intention to treat in all patients who started randomised treatment. Safety was analysed according to treatment received. This trial is registered with ClinicalTrials.gov, NCT02564146, and is completed., Findings: Between May 27, 2016, and May 27, 2021, 325 patients were enrolled. Following three cycles of induction treatment, 174 patients were randomly assigned: 85 to continue receiving standard nab-paclitaxel-gemcitabine, of whom 79 started treatment, and 89 to the alternating treatment schedule, of whom 88 started treatment. Of the 167 patients who started randomised treatment, 88 (53%) were female and 79 (47%) were male. Median overall survival after randomisation was 10·4 months (80% CI 9·2-12·0) in the group that received standard treatment and 10·5 months (10·2-11·1) in the group that received alternating treatment (HR 0·90, 80% CI 0·72-1·13; p=0·56). The most common adverse events of any grade were peripheral neuropathy (59 [74%] of 80 patients in the continuous treatment group vs 53 [62%] of 85 patients in the alternating treatment group) and fatigue (43 [54%] vs 44 [52%]). Treatment-emergent serious adverse events after randomisation occurred in 40 (50%) patients in the continuous treatment group and in 28 (33%) in the alternating treatment group. Fewer treatment-emergent adverse events of grade 3 or higher occurred in patients treated with alternating cycles compared with those receiving standard therapy, especially for peripheral neuropathy (17 [21%] patients in the continuous treatment group vs 12 [14%] in the alternating treatment group) and infections (16 [20%] vs nine [11%]). There were two treatment-related deaths after randomisation, both in the continuous treatment group (one multiple organ dysfunction syndrome, not treated after randomisation, and one interstitial lung disease)., Interpretation: Our findings suggest that a dose-reduced regimen with alternating cycles of nab-paclitaxel-gemcitabine and gemcitabine alone after three induction cycles is associated with similar overall survival to that for standard treatment with nab-paclitaxel-gemcitabine, but with improved tolerability. We therefore propose that a switch to the alternating schedule could be considered in a clinical setting for patients with metastatic pancreatic cancer who have at least stable disease after three cycles of nab-paclitaxel-gemcitabine treatment., Funding: Celgene/Bristol Myers Squibb., Competing Interests: Declaration of interests KD reports honoraria from AstraZeneca and support for travel, accommodation, and expenses from Servier, GSK, Bristol Myers Squibb, and AstraZeneca. SB reports honoraria for scientific presentations from Celgene, Servier, and MSD, fees for consultancy or advisory roles from Celgene, Servier, Incyte, Janssen-Cilag, AstraZeneca, MSD, and Bristol Myers Squibb, and support for travel, accommodation, and expenses from Lilly. MR reports honoraria for speakers' bureaus from Roche, Falk, and Servier and approved patents (EP18783030.2-1109, combination treatment of pancreatic cancer targeting PI3K signalling; EP20206259.2, analysis of tissue samples using quantitative phase-contrast microscopy). TJE reports research funding from Baxalta/Shire, support for travel, accommodation, and expenses from Ipsen, fees for consultancy or advisory roles from Eisai, MSD, Bayer, Roche, Sanofi, Bristol Myers Squibb, Incyte, AstraZeneca, Merck Serono, Pierre Fabre, Servier, Lilly, Ipsen, and Daiichi Sankyo Europe. OW reports honoraria from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, MSD, Novartis, Roche, and Zentiva, consultancy fees from Amgen, Bayer, Bristol Myers Squibb, Celgene, Eisai, Incyte, Ipsen, Merck, MSD, Novartis, Roche, and Servier, and support for travel, accommodation, and expenses from Abbvie, Bayer, Bristol Myers Squibb, Gilead, Ipsen, Medac, Merck, Pierre Fabre, and Roche. DPM reports research funding to his institution from Amgen and Servier, honoraria from Merck Serono, Amgen, Servier, Bristol Myers Squibb, Taiho Pharmaceutical, MSD, Pierre Fabre, Onkowissen, Sanofi, Lilly, Institut für klinische Krebsforschung, AstraZeneca/MedImmune, Incyte, and Takeda, and fees for consultancy or advisory roles from Merck Serono, Amgen, MSD, Roche, Servier, Incyte, Bristol Myers Squibb, Pierre Fabre, Lilly, Cor2Ed, IQvia, and Onkowissen. PM reports grants from Lilly, royalties and licenses from Elsevier, consultancy fees from Lilly and Ipsen, honoraria for speakers' bureaus from Falk, Amgen, and Roche, and support for travel, accommodation, and expenses from Galapagos. DP reports consultancy fees and honoraria paid to his institution from Boehringer Ingelheim, Deciphera, and PharmaMar, support for travel, accommodation, and expenses paid to his institution from PharmaMar, fees for consultancy or advisory roles paid to his institution from Boehringer Ingelheim, Deciphera, PharmaMar, and Thermosome, and research funding paid to his institution from Bristol Myers Squibb, PharmaMar, Roche, EUSA Pharma, and Boehringer Ingelheim. AR-S reports honoraria from Amgen, Roche, Merck Serono, Bristol Myers Squibb, MSD, MCI Group, and AstraZeneca, support for travel, accommodation, and expenses from Roche, Amgen, Pierre Fabre, and MSD, fees for consultancy or advisory roles from Abbvie, Amgen, Boehringer Ingelheim, Roche, Merck Serono, Bristol Myers Squibb, MSD, AstraZeneca, Pierre Fabre, Daiichi Sankyo, Janssen-Cilag, and Servier, and research funding paid to her institution from Roche, Celgene, Ipsen, Amgen, Alexion Pharmaceuticals, AstraZeneca, Lilly, Servier, AIO-Studien, Rafael Pharmaceuticals, Erytech Pharma, and BioNTech. HP reports honoraria from Bristol Myers Squibb and AstraZeneca, support for travel, accommodation, and expenses from Abbvie, iOMEDICO, and Merck, fees for consultancy or advisory roles from Roche, Bristol Myers Squibb, Pfizer, Bayer, Novartis, Takeda, Janssen-Cilag, Gilead, Amgen, Abbvie, GSK, BeiGene, Oncopeptides, Incyte, Seagen, and Kedrion, and leadership and fiduciary roles for PiTri Studien. VH reports research funding paid to his institution from Merck, Amgen, and Roche, fees for consultancy and advisory roles from Merck, Amgen, Roche, MSD, Bristol Myers Squibb, MSD Oncology, Novartis, Pierre Fabre, TERUMO, GSK, Servier/Pfizer, AstraZeneca, Oncosil, and Nordic Bioscience, honoraria from Roche, Amgen, Sanofi, Merck, Servier, Pfizer, Pierre Fabre, AstraZeneca, MSD, and Seagen, and support for travel, accommodation, and expenses from Merck. FK reports research funding from Celgene and consultancy fees from Bayer and Novartis. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)- Published
- 2024
- Full Text
- View/download PDF
42. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).
- Author
-
Witte D, Pretzell I, Reissig TM, Stein A, Velthaus JL, Alig A, Bohnenberger H, Knödler M, Kurreck A, Sulzer S, Beyer G, Dorman K, Fröhlich T, Hegenberg S, Lugnier C, Saborowski A, Vogel A, Lange S, Reichert M, Flade F, Klaas L, Utpatel K, Becker H, Bleckmann A, Wethmar K, Reinacher-Schick A, and Westphalen CB
- Subjects
- Humans, Male, Middle Aged, Retrospective Studies, Female, Aged, Adult, Aged, 80 and over, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Pyridones administration & dosage, Pyridones therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Pyrimidinones administration & dosage, Pyrimidinones therapeutic use, Pyridines therapeutic use, Pyridines administration & dosage, Hydroxychloroquine therapeutic use, Hydroxychloroquine administration & dosage, Piperazines therapeutic use, Piperazines administration & dosage
- Abstract
Background: Preclinical models of pancreatic cancer (PDAC) suggest a synergistic role for combined MEK and autophagy signaling inhibition, as well as MEK and CDK4/6 pathway targeting. Several case reports implicate clinical activity of the combination of either trametinib and hydroxychloroquine (HCQ) in patients with KRAS-mutant PDAC or trametinib with CDK4/6 inhibitors in patients with KRAS and CDKN2A/B alterations. However, prospective data from clinical trials is lacking. Here, we aim to provide clinical evidence regarding the use of these experimental regimens in the setting of dedicated precision oncology programs., Methods: In this retrospective case series, PDAC patients who received either trametinib/HCQ (THCQ) or trametinib/palbociclib (TP) were retrospectively identified across 11 participating cancer centers in Germany., Results: Overall, 34 patients were identified. 19 patients received THCQ, and 15 received TP, respectively. In patients treated with THCQ, the median duration of treatment was 46 days, median progression-free survival (PFS) was 52 days and median overall survival (OS) was 68 days. In the THCQ subgroup, all patients evaluable for response (13/19) had progressive disease (PD) within 100 days. In the TP subgroup, the median duration of treatment was 60 days, median PFS was 56 days and median OS was 195 days. In the TP subgroup, 9/15 patients were evaluable for response, of which 1/9 showed a partial response (PR) while 8/9 had PD. One patient achieved a clinical benefit despite progression under TP., Conclusion: THCQ and TP are not effective in patients with advanced PDAC harboring KRAS mutations or alterations in MAPK/CDKN2A/B., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
43. Treosulfan-Versus Melphalan-Based Reduced Intensity Conditioning in HLA-Haploidentical Transplantation for Patients ≥ 50 Years with Advanced MDS/AML.
- Author
-
Fraccaroli A, Stauffer E, Haebe S, Prevalsek D, Weiss L, Dorman K, Drolle H, von Bergwelt-Baildon M, Stemmler HJ, Herold T, and Tischer J
- Abstract
Relapse and regimen-related toxicities remain major challenges in achieving long-term survival, particularly among older patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have demonstrated the feasibility of treosulfan-based conditioning, noting stable engraftment and low non-relapse mortality (NRM) in patients undergoing HLA-matched allo-HSCT. However, data on treosulfan-based conditioning in the HLA-haploidentical transplantation (HaploT) setting are limited. We retrospectively compared conditioning with fludarabine-cyclophosphamide (FC)-melphalan (110 mg/m
2 ) and FC-treosulfan (30 g/m2 ) prior to HaploT using post-transplantation cyclophosphamide (PTCy) in patients with high-risk MDS/AML patients ≥ 50 years, transplanted from 2009-2021 at our institution ( n = 80). After balancing patient characteristics by a matched-pair analysis, we identified twenty-one matched pairs. Two-year OS and LFS were similar among the groups (OS 66% and LFS 66%, p = 0.8 and p = 0.57). However, FC-melphalan was associated with a significantly lower probability of relapse compared to FC-treosulfan (0% vs. 24%, p = 0.006), counterbalanced by a higher NRM (33% vs. 10%, p = 0.05). Time to engraftment and incidences of acute and chronic graft-versus-host disease (GvHD) did not differ significantly. In conclusion, HaploT using FC-treosulfan in combination with PTCy in patients aged ≥50 years with MDS/AML appears safe and effective, particularly in advanced disease stages. We confirm the favorable extramedullary toxicity profile, allowing for potential dose intensification to enhance antileukemic activity.- Published
- 2024
- Full Text
- View/download PDF
44. Neuropsychological Profiles of Deployment-Related Mild Traumatic Brain Injury: A LIMBIC-CENC Study.
- Author
-
de Souza NL, Lindsey HM, Dorman K, Dennis EL, Kennedy E, Menefee DS, Parrott JS, Jia Y, Pugh MJV, Walker WC, Tate DF, Cifu DX, Bailie JM, Davenport ND, Martindale SL, O'Neil M, Rowland JA, Scheibel RS, Sponheim SR, Troyanskaya M, Wilde EA, and Esopenko C
- Subjects
- Humans, Male, Adult, Female, Cross-Sectional Studies, Middle Aged, Longitudinal Studies, Veterans psychology, Prospective Studies, Military Deployment psychology, Post-Concussion Syndrome psychology, Post-Concussion Syndrome epidemiology, Quality of Life, Stress Disorders, Post-Traumatic epidemiology, Stress Disorders, Post-Traumatic psychology, Stress Disorders, Post-Traumatic etiology, Brain Concussion psychology, Brain Concussion complications, Brain Concussion epidemiology, Neuropsychological Tests, Military Personnel psychology
- Abstract
Background and Objectives: Traumatic brain injury (TBI) is a concern for US service members and veterans (SMV), leading to heterogeneous psychological and cognitive outcomes. We sought to identify neuropsychological profiles of mild TBI (mTBI) and posttraumatic stress disorder (PTSD) among the largest SMV sample to date., Methods: We analyzed cross-sectional baseline data from SMV with prior combat deployments enrolled in the ongoing Long-term Impact of Military-relevant Brain Injury Consortium-Chronic Effects of Neurotrauma Consortium prospective longitudinal study. Latent profile analysis identified symptom profiles using 35 indicators, including physical symptoms, depression, quality of life, sleep quality, postconcussive symptoms, and cognitive performance. It is important to note that the profiles were determined independently of mTBI and probable PTSD status. After profile identification, we examined associations between demographic variables, mTBI characteristics, and PTSD symptoms with symptom profile membership., Results: The analytic sample included 1,659 SMV (mean age 41.1 ± 10.0 years; 87% male); among them 29% (n = 480) had a history of non-deployment-related mTBI only, 14% (n = 239) had deployment-related mTBI only, 36% (n = 602) had both non-deployment and deployment-related mTBI, and 30% (n = 497) met criteria for probable PTSD. A 6-profile model had the best fit, with separation on all indicators ( p < 0.001). The model revealed distinct neuropsychological profiles, representing a combination of 3 self-reported functioning patterns: high (HS), moderate (MS), and low (LS), and 2 cognitive performance patterns: high (HC) and low (LC). The profiles were (1) HS/HC: n=301, 18.1%; (2) HS/LC: n=294, 17.7%; (3) MS/HC: n=359, 21.6%; (4) MS/LC: n=316, 19.0%; (5) LS/HC: n=228, 13.7%; and (6) LS/LC: n=161, 9.7%. SMV with deployment-related mTBI tended to be grouped into lower functioning profiles and were more likely to meet criteria for probable PTSD. Conversely, SMV with no mTBI exposure or non-deployment-related mTBI were clustered in higher functioning profiles and had a lower likelihood of meeting criteria for probable PTSD., Discussion: Findings suggest varied symptom and functional profiles in SMV, influenced by injury context and probable PTSD comorbidity. Despite diagnostic challenges, comprehensive assessment of functioning and cognition can detect subtle differences related to mTBI and PTSD, revealing distinct neuropsychological profiles. Prioritizing early treatment based on these profiles may improve prognostication and support efficient recovery.
- Published
- 2024
- Full Text
- View/download PDF
45. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
- Author
-
Weiss L, Heinemann V, Fischer LE, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Vehling-Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, von Bergwelt-Baildon M, Boeck S, and Haas M
- Subjects
- Humans, Deoxycytidine therapeutic use, Patient Selection, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gemcitabine, Pancreatic Neoplasms
- Abstract
Purpose: To analyze the 3-month life expectancy rate in pancreatic cancer (PC) patients treated within prospective trials from the German AIO study group., Patients and Methods: A pooled analysis was conducted for patients with advanced PC that were treated within five phase II/III studies conducted between 1997 and 2017 (Gem/Cis, Ro96, RC57, ACCEPT, RASH). The primary goal for the current report was to identify the actual 3-month survival rate, a standard inclusion criterion in oncology trials., Results: Overall, 912 patients were included, 83% had metastatic and 17% locally advanced PC; the estimated median overall survival (OS) was 7.1 months. Twenty-one percent of the participants survived < 3 months, with a range from 26% in RC57 to 15% in RASH. Significant predictors for not reaching 3-month OS were > 1 previous treatment line (p < 0.001) and performance status (p < 0.001)., Conclusions: Despite the definition of a life expectancy of > 3 months as a standard inclusion criterion in clinical trials for advanced PC, a significant proportion of study patients does not survive > 3 months., Trial Registration Numbers: NCT00440167 (AIO-PK0104), NCT01729481 (RASH), NCT01728818 (ACCEPT)., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
46. Unresectable biliary tract cancer: Current and future systemic therapy.
- Author
-
Zhang D, Dorman K, Westphalen CB, Haas M, Ormanns S, Neumann J, Seidensticker M, Ricke J, De Toni EN, Klauschen F, Algül H, Reisländer T, Boeck S, and Heinemann V
- Subjects
- Humans, Immunotherapy methods, Molecular Targeted Therapy methods, Biliary Tract Neoplasms therapy, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms pathology
- Abstract
For decades, treatment of advanced biliary tract cancer (BTC) was confined to the use of chemotherapy. In recent years however, the number of therapeutic options available for patients with unresectable BTC have drastically increased, with immunotherapy and targeted treatment gradually joining the ranks of guideline-recommended treatment regimens. The aim of the present review is to summarise the current knowledge on unresectable BTC focusing on epidemiology, anatomical distribution and current strategies for systemic treatment. We further outline ongoing clinical trials and provide an outlook on future therapeutic interventions. In the realm of gastrointestinal malignancies, the increasing number of systemic treatment options for BTC is finally delivering on the longstanding commitment to personalised oncology. This emphasises the need for considering a comprehensive genomic-based pathology assessment right from the initial diagnosis to fully leverage the expanding array of therapeutic options that have recently become accessible., Competing Interests: Declaration of Competing interest DZ reported receiving honoraria from AstraZeneca, receiving research funding for the institution from Milteny and travel as well as accommodation expenses from AstraZeneca and Amgen. KD has received travel support from Servier, GSK and BMS, as well as honoraria from AstraZeneca. CBW has received honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, SIRTeX and Taiho; served on advisory boards for Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire/Baxalta, Rafael Pharmaceuticals, RedHill and Roche; has received travel support by Bayer, Celgene, Janssen, RedHill, Roche, Servier and Taiho and research grants (institutional) by Roche. MH reported receiving travel support from Servier and honoraria for scientific presentations from Falk Foundation. SO reported no conflict of interest. JN reported no conflict of interest. MS reported receiving lecture fees from AstraZeneca, Bayer Healthcare, Cook Medical, Sirtex Medical, LIAM GmbH, Balt and research grants from AstraZeneca, Roche, Bayer Healthcare, Sirtex Medical. JR reported reported no conflict of interest. EDT has served as a paid consultant for AstraZeneca, Bayer, BMS, EISAI, Eli Lilly & Co, MSD, Mallinckrodt, Omega, Pfizer, IPSEN, Terumo and Roche. He has received reimbursement of meeting attendance fees and travel expenses from Arqule, Astrazeneca, BMS, Bayer, Celsion and Roche and lecture honoraria from BMS and Falk. He has received third-party funding for scientific research from Arqule, AstraZeneca, BMS, Bayer, Eli Lilly and IPSEN and Roche. FK reported no conflict of interest. HA reported receiving consulting honoraria from Pfizer, Servier. TR reported being employee of Servier Deutschland GmbH. SB had a consulting and advisory role for Celgene, Servier, Incyte, Fresenius, Janssen-Cilag, AstraZeneca, MSD and BMS and received honoraria for scientific presentations from Roche, Celgene, Servier and MSD. VH received honoraria for talks and advisory board role for Merck, Amgen, Roche, Sanofi, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS; MSD, Novartis, Terumo, On- cosil, NORDIC, Seagen, GSK. Research funding from Merck, Amgen, Roche, Sanofi, Boehringer-Ingelheim, SIRTEX, Servier., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
- Author
-
Zhang D, Benedikt Westphalen C, Quante M, Waldschmidt DT, Held S, Kütting F, Dorman K, Heinrich K, Weiss L, Boukovala M, Haas M, Boeck S, Heinemann V, and Probst V
- Subjects
- Humans, Afatinib adverse effects, Deoxycytidine, Paclitaxel, Albumins, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols adverse effects, Gemcitabine, Pancreatic Neoplasms pathology
- Abstract
Purpose: The combination of gemcitabine/nab-paclitaxel is an established standard treatment in the first-line treatment of metastatic ductal adenocarcinoma of the pancreas (mPDAC). Afatinib, an oral second-generation pan ErbB family tyrosine kinase inhibitor, has shown promising pre-clinical signs in the treatment of pancreatic cancer. The aim of this phase 1b trial was to determine the maximum tolerated dose (MTD) of afatinib in combination with gemcitabine/nab-paclitaxel in patients with mPDAC., Methods: Treatment naïve patients (≥18 years) with histologically proven mPDAC and good performance status (ECOG 0/1) were enrolled to receive gemcitabine/nab-paclitaxel in combination with afatinib. Treatment was continued until disease progression, or unacceptable toxicity. The primary endpoint MTD was determined using a 3 + 3 design. Treatment started at dose level 0 with intravenous gemcitabine/nab-paclitaxel 1000 mg/m
2 / 125 mg/m2 (day 1, 8, 15 of a 28-day cycle) + oral afatinib 30 mg daily. At dose level + 1 afatinib was increased to 40 mg. Secondary endpoints included safety parameters and exploratory endpoints evaluated treatment efficacy., Results: Twelve patients were included in this trial, and 11 patients were treated and analysed in the safety and full analysis set (FAS). At dose level 0 the first three patients did not experience a dose-limiting toxicity (DLT). At dose leve (DL) + 1 two patients experienced a DLT. Accordingly, enrolment continued at DL 0 with three more patients, of which one experienced DLT (skin rash ≥ CTCAE grade 3). Seven patients (63.6%) experienced at least one treatment-emergent serious adverse event (TESAE), with four patients (36.4%) experiencing TESAEs grade 3-5 related to the study medication. In the FAS, the objective response rate (ORR) was 36.4%, median progression-free survival (PFS) was 3.5 months and median overall survival in nine evaluable patients was 7.5 months., Conclusions: In this phase 1b clinical trial, the MTD of gemcitabine/nab-paclitaxel (1000 mg/m2 / 125 mg/m2 ) and afatinib (30 mg) was established. In a cohort of 11 patients, the combination showed an acceptable safety profile., Competing Interests: Declaration of Competing Interest DZ reported receiving honoraria from AstraZeneca, receiving research funding for the institution from Milteny and travel as well as accommodation expenses from AstraZeneca and Amgen. CBW has received honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, SIRTeX, and Taiho; served on advisory boards for Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire/Baxalta, Rafael Pharmaceuticals, RedHill, and Roche; has received travel support by Bayer, Celgene, Janssen, RedHill, Roche, Servier, and Taiho and research grants (institutional) by Roche. MQ, DTW, FK, KH and MB report no conflict of interest. SW reported being employee of ClinAssess GmbH KD has received travel support from Servier, GSK, and BMS, as well as honoraria from AstraZeneca. LW received honoraria for scientific presentations from Roche and Servier and travel accommodation expenses from Amgen. MH reported receiving travel support from Servier and honoraria for scientific presentations from Falk Foundation. SB had a consulting and advisory role for Celgene, Servier, Incyte, Fresenius, Janssen-Cilag, AstraZeneca, MSD, and BMS, and received honoraria for scientific presentations from Roche, Celgene, Servier, and MSD. VH received honoraria for talks and advisory board role for Merck, Amgen, Roche, Sanofi, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS; MSD, Novartis, Terumo, On- cosil, NORDIC, Seagen, GSK. Research funding from Merck, Amgen, Roche, Sanofi, Boehringer-Ingelheim, SIRTEX, Servier. VP reported receiving travel support from Nordic Pharma., (Copyright © 2024. Published by Elsevier Ltd.)- Published
- 2024
- Full Text
- View/download PDF
48. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.
- Author
-
Weiss L, Fischer LE, Heinemann V, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, Boeck S, and Haas M
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Germany, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols pharmacology, Adult, Prospective Studies, Aged, 80 and over, Prognosis, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms mortality, Pancreatic Neoplasms pathology
- Abstract
Background: Over the past two decades, our group has conducted five multicenter trials focusing on first-line systemic therapy for patients with advanced pancreatic cancer. The current pooled analysis was designed to evaluate prognosis over time and the impact of clinical characteristics on survival., Patients and Methods: Individual patient data were derived from five prospective, controlled, multicenter trials conducted by the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO): 'Gem/Cis', 'Ro96', 'RC57', 'ACCEPT' and 'RASH', which recruited patients between December 1997 and January 2017., Results: Overall, 912 patients were included. The median overall survival (OS) for all assessable patients was 7.1 months. OS significantly improved over time, with a median OS of 8.6 months for patients treated from 2012 to 2017 compared with 7.0 months from 1997 to 2006 [hazard ratio (HR) 1.06; P < 0.004]. Eastern Cooperative Oncology Group performance status (HR 1.48; P < 0.001), use of second-line treatment (HR 1.51; P < 0.001), and Union for International Cancer Control (UICC) stage (III versus IV) (HR 1.34, P = 0.002) had a significant impact on OS. By contrast, no influence of age and gender on OS was detectable. Comparing combination therapy with single-agent chemotherapy did not demonstrate a survival benefit, nor did regimens containing epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as afatinib or erlotinib, compared with chemotherapy-only arms. Patients with early-onset pancreatic cancer (age at study entry of ≤50 years, n = 102) had a similar OS compared with those >50 years (7.1 versus 7.0 months; HR 1.13; P = 0.273). The use of a platinum-containing regimen was not associated with better outcomes in patients with early-onset pancreatic cancer., Conclusions: Within this selected group of patients treated within prospective clinical trials, survival has shown improvement over two decades. This effect is likely attributable to the availability of more effective combination therapies and treatment lines, rather than to any specific regimen, such as those containing EGFR-TKIs. In addition, concerning age and sex subgroups, the dataset did not provide evidence for distinct clinical behavior., Competing Interests: Disclosure LW has received honoraria for scientific presentations and reports an advisory board role in Roche and Servier; and travel accommodation expenses from Amgen. VH has received honoraria for talks and advisory board role from Merck, Amgen, Roche, Sanofi, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS, MSD, Novartis, Terumo, OncoSil, NORDIC, Seagen, and GSK; and research funding from Merck, Amgen, Roche, Sanofi, Boehringer-Ingelheim, SIRTEX, and Servier. ARS has received honoraria from Amgen, Roche, Merck Serono, BMS, MSD, MCI Group, and AstraZeneca; for advisory and consultancy from Amgen, Roche, Merck Serono, BMS, MSD, AstraZeneca, and Pierre Fabre; research grant/funding from Roche, Celgene, Ipsen, Amgen, Alexion Pharmaceuticals, AstraZeneca, Lilly, Servier, AIO-Studien-gGmbH, Rafael Pharmaceutics, Erytech Pharma, and BioNTech; and travel expenses Roche, Amgen, and Pierre Fabre. JTS receives honoraria as a consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche/Genentech, and Servier; his institution receives research funding from Abalos Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisbach Bio, and Roche/Genentech; and he holds ownership and serves on the board of directors of Pharma15, all outside the submitted work. MS has received honoraria from Lilly, Roche, and Servier. KD has received travel support from Servier, GSK, and BMS; as well as honoraria from AstraZeneca. DZ has received honoraria and travel support from AstraZeneca. CBW has received honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, Sirtex, and Taiho; has served on advisory boards for Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire/Baxalta, Rafael Pharmaceuticals, RedHill, and Roche; has received travel support from Bayer, Celgene, Janssen, RedHill, Roche, Servier, and Taiho; research grants (institutional) from Roche; serves as an officer for European Society of Medical Oncology (ESMO), Deutsche Krebshilfe (DKH), and Arbeitsgemeinschaft Internistische Onkologie (AIO); and is a member of the EU Commission expert group: Mission Board for cancer. SB had a consulting and advisory role for Celgene, Servier, Incyte, Fresenius, Janssen-Cilag, AstraZeneca, MSD, and BMS; and has received honoraria for scientific presentations from Roche, Celgene, Servier, and MSD. MH has received travel support from Servier and honoraria for scientific presentations from the Falk Foundation. All other authors have declared no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
49. A rare case of locally advanced DNA mismatch-repair-deficient adenocarcinoma of the colon in a 16-year-old male treated with neoadjuvant immunotherapy and single-incision laparoscopic resection.
- Author
-
Zhang D, Muensterer O, Neumann J, Dorman K, Rassner M, Schmid I, and Heinemann V
- Subjects
- Brain Neoplasms, Male, Adolescent, DNA, Neoplastic Syndromes, Hereditary, Humans, Neoadjuvant Therapy, Colorectal Neoplasms
- Published
- 2023
- Full Text
- View/download PDF
50. Early clinical trial unit tumor board: a real-world experience in a national cancer network.
- Author
-
Weiss L, Dorman K, Boukovala M, Schwinghammer F, Jordan P, Fey T, Hasselmann K, Subklewe M, Bücklein V, Bargou R, Goebeler M, Sayehli C, Spoerl S, Lüke F, Heudobler D, Claus R, von Luettichau I, Lorenzen S, Lange S, Westphalen CB, von Bergwelt-Baildon M, Heinemann V, and Gießen-Jung C
- Abstract
Purpose: Early clinical trials are the first step into clinical therapies for new drugs. Within the six Bavarian university-based hospitals (Augsburg, Erlangen, Regensburg, Munich (LMU and TU), Würzburg) we have enrolled a virtual network platform for patient discussion., Methods: The virtual Early Clinical Trial Unit Tumor Board (ECTU Tumor Board) is a secured web-based meeting to evaluate early clinical trial options for patients, where representatives from local ECTUs participate. We retrospectively analyzed patient cases discussed between November 2021 and November 2022., Results: From November 2021 to November 2022, a total of 43 patients were discussed in the ECTU Tumor Board. Median age at diagnosis was 44.6 years (range 10-76 years). The median number of previous lines of therapies was 3.7 (range 1-9 therapies) including systemic treatment, surgery, and radiation therapy. A total of 27 different tumor entities were presented and 83.7% (36/43) patients received at least one trial recommendation. In total, 21 different active or shortly recruiting clinical trials were recommended: ten antibody trials, four BiTE (bispecific T cell engager) trials, six CAR (chimeric antigen receptor) T-cell trials, and one chemotherapy trial. Only six trials (28.6%) were recommended on the basis of the previously performed comprehensive genetic profiling (CGP)., Conclusion: The ECTU Tumor Board is a feasible and successful network, highlighting the force of virtual patient discussions for improving patient care as well as trial recruitment in advanced diseases. It can provide further treatment options after local MTB presentation, aiming to close the gap to access clinical trials., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.